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ABSTRACT 
We have developed the first protease specificity engineering technology intended to serve as a 
general-purpose source of target-specific protease mutants with potential therapeutic 
applications. We used this E. coli-based screening system to isolate multiple HIV protease 
mutants with improved proteolytic specificities and activities toward an octapeptide taken from 
the beta-amyloid peptide (Abeta) implicated in Alzheimer's Disease. Quantitative Western 
blotting of E. coli extracts revealed approximately 20- and 30-fold increases in proteolytic 
specificity and activity, respectively, toward the Abeta octapeptide relative to a native octameric 
substrate of the wild type HIV protease. 
Our HIV protease specificity engineering system requires no expensive reagents or equipment 
and can be conveniently adopted by any laboratory. The system employs the E. coli 
betagalactosidase protein as a reporter for protease activity. The employment of pgal as a 
reporter gene allows facile bluelwhite E. coli colony screening of mutant protease libraries. 
Additionally, mutant protease specificity profiles are readily assessed via E. coli liquid culture 
pgal activity assays. Mutant protease library screening stringency is conveniently controlled by 
the amount of arabinose added to bluelwhite screening plates. 
We have identified Alzheimer's Disease, Parkinson's Disease, HIV and Hepatitis C as maladies 
that may be treated with target-specific proteases obtained by using our system. We are eager 
to observe the future pursuit of both these and additional biomedical applications for target- 
specific proteases. 
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1) INTRODUCTION 
In vitro antibody library screening technologies enable the isolation of antibodies capable of 
specifically binding to almost any chosen target protein. These screening platforms have come 
to serve as general-purpose sources of target-specific, high affinity antibodies with therapeutic 
potential. These powerful antibody library screening systems have facilitated the development 
of recombinant antibodies that have either been approved or are presently being evaluated as 
therapies for a wide range of diseases such as Alzheimer's Disease, cancer and Rheumatoid 
arthritis (Hoogenboom, 2005). 
An in vitro screening technology serving as a general-purpose source of highly active, target- 
specific proteases may enable the development of proteases with a similarly broad range of 
therapeutic applications. Recent research, aimed at understanding how enzymes adapt to 
utilize novel substrates (O'Loughlin, 2006), employed an E. coli-based screening system to 
isolate an HIV protease mutant with improved specificity toward a peptide sequence taken from 
the human tumor necrosis factor-alpha (TNF-a) protein. O'Loughlin's screening system has not 
been shown to accommodate a range of target sequences that are cleaved with varying 
efficiencies by the wild type HIV protease. Additionally, O'Loughlin's screening system does not 
contain a mutant library screening stringency control feature. Given these two observations, it 
reasonable to assume that O'Laughlin's screening system lacks the ability to accommodate a 
wide range of chosen target sequences. As such, O'Laughlin's screening system is not well 
suited to serve as a general-purpose source of target-specific proteases. 
Varadarajan (2005) used an E. coli-based screening system to isolate a variant of the OmpT 
protein, an outer membrane endopeptidase of E. coli, with improved activity and specificity 
toward an Ala-Arg peptide bond that is not proteolyzed by the wild type OmpT protein. The 
narrow specificity of the wild type OmpT protease however, which cleaves substrates at ArgArg 
peptide bonds, precludes the use of Varadarjan's system as a source of proteases with 
improved specificities toward a wide range of chosen target sequences. 
We have successfully developed the first protease screening technology intended to serve 
as a general-purpose source of target-specific protease mutants with potential therapeutic 
applications. This E. coli-based screening system has enabled the rapid and facile isolation of 
multiple HIV protease mutants with improved specificities and activities toward an octapeptide 
taken from the beta-amyloid peptide (Abeta) implicated in Alzheimer's Disease. In contrast to 
the other mutant protease library screening systems described above, our system has been 
designed to accommodate a wide range of chosen target sequences. Our HIV protease 
specificity engineering system employs the gene most commonly used in E. coli-based protein 
activity reporter systems, betagalactosidase (Shuman, 2003), as a proxy for mutant HIV 
protease activity. By basing our HIV protease specificity engineering system on a set of 
established protocols requiring no expensive equipment or reagents, we have created a 
technology that can be conveniently adopted by any laboratory seeking to develop engineered 
protease therapies. A collection of potential therapeutic applications for specificity-engineered 
proteases is described below. 
Alzheimer's Disease is a condition in which Abeta, a peptide with multiple isoforms of up to 
43 amino acids, forms toxic aggregates in the human brain. These toxic aggregates trigger 
neurodegeneration that causes afflicted individuals to suffer from progressive memory loss. 
This progressive memory loss leads to the need for total care from others and eventually proves 
fatal. The economic impact of Alzheimer's Disease, estimated to be greater than $1 00billionIyr 
(www.alzheimersfactsforhealth.org) in the United States alone, is staggering. Although 
medications can slow the progression of the memory loss associated with Alzheimer's Disease, 
there is no treatment or cure for the disease. 
One approach for developing Alzheimer's Disease treatments has been to identify either 
small molecules (Gestwicki, 2004) or peptides (Watanabe, 2002) that bind to Abeta and inhibit 
the formation of toxic aggregates. This body of work has inspired our vision for using 
engineered HIV protease mutants to inhibit Abeta aggregation. HIV protease mutants, 
engineered for high specificity and activity toward Abeta, may cleave the peptide into smaller 
fragments that do not form toxic aggregates. Such proteases are an unexplored and exciting 
potential approach to Alzheimer's Disease therapy. 
Engineered proteases may also be pursued as treatments for a second incurable condition 
caused by the formation of toxic protein aggregates, Parkinson's Disease. Aggregates of alpha- 
synuclein, an -14.8kD protein expressed in brain tissue, causes the 1.5 million Americans 
afflicted with Parkinson's Disease to suffer from progressively worsening tremors, rigidity, slow 
movement and poor balance (www.apdaparkison.org). Engineered HIV protease mutants, with 
high specificities and activities toward alpha-synuclein, may be pursued as therapeutic inhibitors 
of alpha-synuclein aggregation. 
As described below, we believe that specificity-engineered proteases may be important new 
additions to the existing collection of AIDS therapies. HIV replication occurs primarily within the 
cytoplasm of T cells and macrophages that have been infected by the virus. This replication is 
dependent upon correct proteolysis of three polypeptide precursors. The HIV protease cleaves 
these three precursor polypeptides at twelve distinct sites (Ikuta, 2000). Proteolysis of the HIV 
polypeptide precursors at positions other than the twelve native cleavage sites would be 
expected to prevent normal processing of the polypeptide precursors and disrupt HIV 
replication. HIV protease mutants, engineered to cleave nonnative sites in the precursor 
polypeptides, may retard or prevent HIV replication via the aberrant proteolysis described 
above. A lentiviral vector has been used to transduce cultured T4 immune cells with a 
recombinant gene coding for a membrane-bound protein inhibitor of HIV cell entry (Perez, 
2005). This successful transfection encourages the exploration of lentiviral delivery of 
engineered mutant HIV protease genes as a novel form of HIV therapy. 
Lentiviral delivery of engineered mutant HIV protease genes may also be employed to treat 
the 170 million people, 4 million of them Americans, who are currently infected with Hepatitis C 
Virus (HCV). HCV is analogous to HIV in that a protease from the viral genome is necessary for 
correct polypeptide precursor proteolysis and viral replication. This similarity motivates the 
pursuit of an engineered HIV mutant protease-based HCV therapy akin to the treatment for HIV 
described above. 
We believe that the potential impact of the above therapeutic applications for target-specific 
HIV protease mutants provides a testament to the value of our protease specificity engineering 
system. We look forward the deployment of the readily implemented technology that we have 
developed and we are eager to observe the biomedical research progress that it will enable. 
We begin the presentation of our work with a description of the materials and methods used 
to construct the plasmids and E. coli strain comprising our protease specificity engineering 
system. Mutant HIV protease library screening and individual mutant HIV protease clone 
specificity characterization protocols are subsequently described. Our account of the materials 
and methods that we have employed concludes with the immunoblotting protocols used to 
quantify mutant protease specificity and activity improvements. 
Our presentation of the results obtained opens with a description of the protease specificity 
engineering system that we have constructed. We subsequently provide data that demonstrate 
our protease specificity engineering system's ability to accommodate a range of target 
sequences. The target sequence accommodation data are followed by the results of mutant 
HIV protease library screens. These library screens yielded HIV protease mutants with 
improved activities and specificities toward an octapeptide target taken from the Abeta peptide 
described above. We close our presentation of the results obtained with immunoblotting data 
that have been used to quantify improvements in mutant HIV protease specificity and activity 
toward the Abeta target. 
The results presented set the stage for a discussion of how the features of our protease 
specificity engineering system enabled the isolation of HIV protease mutants with improved 
specificity and activity toward the Abeta target. We subsequently present explanations for the 
observed improvements in HIV mutant protease activity and specificity toward the Abeta target. 
These explanations are based on our examination of images of HIV protease-native peptide 
substrate co-crystal structures. Finally, we combine our findings with a review of the relevant 
protease specificity engineering literature to identify avenues for augmenting the already 
satisfying performance of our protease specificity engineering system. 
2) MATERIALS AND METHODS 
2.1) Oliaonucleotides 
QuikChange XL Site Directed Mutagenesis primers are denoted by "*". Underlined bases in 
these oligonucleotide primer sequences denote sites of mutation. For overlap extension 
mutagenesis PCR primers, "N" denotes the Integrated DNA Technologies (Coralville, IA) 
"machine mix" blend of all 4 bases, where "V" denotes "machine mix" blend of A, G and C and 
" B  denotes the "machine mix" blend of T, C and G. 
Pbrsqrt: 5'-CTTTCACCAGCGTTTCTGGGTGAGC-3' 
Scprleft: 5'-GCTATCGCTACGTGACTGGGTC-3' 
LthvNco: 5'-CCGCCATGGGACCTCAGATCACTCTTTGGCAACGACC-3' 
LthfSpehvpr: 5'-AATATAACTAGTACCAAAATTTAAAGTGCAACCAATCTGAGTC-3' 
RthvPme: 5'-CGGTTTAAACTCACCTAAAAATTTAAAGTGCAACCAATCTGAGTC-3', 
Sperthf hvpr: 5'-TATTATACTAGTTCTGGGCCTCAGATCACTCTTTGGCAACGACC-3' 
Besttpdlgly: 5'-CGGATAACAATTTCACACAGGAAACAGCCATGCCTCAGATCAC-3' 
Bestbtdlgly: 5'-GTGATCTGAGGCATGGCTGTTTCCTGTGTGAAATTGTTATCCG-3' 
*35B1 Otop: 
5'-CCCAGGCTTGACACTTTATGCTTCCGGCTCGTATG-GTGAGC-3' 
*35B1 Obot: 
5'-GCTCACAATTCCACACAICATACGAGCCGGAAGCATAAAGTGTsAAGCCTGGG-3' 
LeftHf232728Rt: 5'-TAATACTGTATCATCNNNNNNTGTATCTAANNNAGCTTCCTTTAG-3' 
LeftHf283032Rt: 5'-TTAGATACAGGANNNGATNNNACANNNTTAGAAGAAATGAGTTTG-3 
LeftHf474849Rt: 5'-AAACCAAAAATG NNN N NNNN NATTGGAGGGTTTTATCAAAGTAAGA-3' 
232728RtHfLeft: 5'-CTAAAGGAAGCTNNNTTAGATACANNNNNNGATGATACAGTATTA-3' 
283032RtHf Left: 5'-CATTTCTTCTAANNNTGTNNNATCTGCTCCTGTATCTAATAGAGC-3' 
474849RtHf Left: 5'-AAAACCTCCAATNNNNNNNNNCATTTTTGGTTTCCATCTTCCTGG-3' 
Lhfbt30: 5'-CATTTCTTCTAATACTGTVNNATCTGCTCCTGTATCTAATAGAGC-3' 
30Rhftop: 5'-TTAGATACAGGAGCAGATNNBACAGTATTAGAAGAAATGAGTlTG-3' 
Lhf bt30: 5'-CATTTCTTCTAATACTGTVNNATCTGCTCCTGTATCTAATAGAGC-3' 
30Rhftop: 5'-TTAGATACAGGAGCAGATNNBACAGTATTAGAAGAAATGAGmG-3' 
Pbadtermrite: 5'-CACCCTAGGCGTTGCTTCGCAACGTTCAAATCC-3' 
Leftpbdamp: 5'-CACGTTAACGGACGAAGCAGGGATTCTGCAAACC-3' 
Pcyc3800: 5'-GCATACTCTGCGACATCGTATAAC-3' 
Pbadlt: 5'-CGTCACACTTTGCTATGCCATAGC-3' 
Rtpbad: 5'-CGTTTCACTTCTGAGTTCGGCATG-3' 
NCOCI It: 5'-CTTGACCATGGGAAGCACAAAAAAGAAACCATTAACACAAGAGCA-3' 
Pmecl rt: 5'-CTTGAGTTTAAACTCAGCCAAACGTCTCTTCAGGCCACTGACTAG-3' 
*Nhecl top: 
5'-CTCATGTTCAGGCuGCATGTTCTCACCTAAGCTTAGAACCTTTACCAAAGGTG-3' 
*Nhebotcl : 
5'-CACCTTTGGTAAAGGTTCTAAGCTTAGGTGAGMCATGCuGCCTGAACATGAG-3' 
'Nheqctp: 5'-CGGACATCAGCGITAGCGGAGTGTATACTGGC-3' 
*N hebtqc: 5'-GCCAGTATACACTCCGCTAACGCTG ATGTCCG-3' 
Abetatop: 5'-CTAGCGGTGGCAAGCTGGTGTTCTTTGCAGAAGATGGCGGTG-3' 
Botabeta: 5'-CTAGCACCGCCATCTTCTGCAAAGAACACCAGCTTGCCACCG-3' 
Uncuttop: 5'-CTAGCGGTGGCTGCGCAAAGAAAATCGTGAGCGATGGCGGTG-3' 
Botuncut: 5'-CTAGCACCGCCATCGCTCACGATTTTCTTTGCGCAGCCACCG-3' 
Phage4B4l I tp: 5'-CTAGCGGTGGCTCTGGTATTTTTCTGGAAACCTCCCTGGGCGGTG-3' 
Phage4B411 bt: 5'-CTAGCACCGCCCAGGGAGGTTTCCAGAAAAATACCAGAGCCACCG-3' 
MacaHl tp: 5'-CTAGCGGTGGCAGCCAAAATTACCCTATTGTGCAGGGCGGTG-3' 
MacaH 1 bt: 5'-CTAGCACCGCCCTGCACAATAGGGTAATTTTGGCTGCCACCG-3' 
Hivmuttp: 5'-CTAGCGGTGGCAGCCAAAATTACCCTATTGGGCAGGGCGGTG-3' 
Mivmutbt: 5'-CTAGCACCGCCCTGCCCAATAGGGTAATTTTGGCTGCCACCG-3' 
*48asntop: 5'-GG ATGGG GCAGTCAGGCGTTMTGCTTTATTTAATG GCATCAATGC-3' 
'48asnbot": 5'-GCATTGATGCCATTAAATAAAGCATJAACGCCTGACTGCCCCATCC-3' 
Pbrsqrt: 5'-CTTTCACCAGCGTTTCTGGGTGAGC-3' 
Scprleft: 5'-GCTATCGCTACGTGACTGGGTC-3' 
2.2) Construction of Protease Activitv Reporter Strains 
E. coli strain RPI 58, which is devoid of the entire arabinose and lactose operons, was 
constructed as follows: Strain BW27786 [F- (DE(araBAD)567 DE(araFGH) @(AaraEp PCPIB 
araE)] (Khlebnikov, 2001), from the Yale E. coli Genetic Stock Center, was transduced to 
tetracycline resistance with PI "" phage grown on strain JCB40 [F- A(gpt-proAB-arg-1ac)Xlll 
zaj::Tnla] from Dr. J.K. Joung at Massachusetts General Hospital. Tetracycline-resistant 
colonies were screened for pro- and lac- phenotypes. 
E. coli strain RPI 64 was created by moving the F' episome, FEI 64, from E. coli strain 
KJI 71 2 [Ahid3463 A(gpt-proAB-arg-lac)Xlll zaj::Tn la] (J.K. Joung) via conjugation as described 
by Whipple (1 998). The FE164 F' episome in strain RP164 contains both a kanamycin 
resistance gene and the entire E. coli lac operon. The lac promoter region upstream of the lac 
operon contains one promoter-weakening mutation (LATAAT+CATAAT) in the -1 0 box and is 
identical to the lac promoter region of plasmid pFWI 1-P2 described in Whipple. The FE164 F' 
episome also features a lambda c l  repressor operator binding site, 
OR2 (5'-TAACACCGTGCGTGTTG-3'), centered at 62 bases upstream of the lac operon 
transcriptional start site. 
Cells were plated onto McConkey arabinose agar (509 McConkey agar, 5glliter L-arabinose 
(Sigma-Aldrich, St. Louis, MO)) plates containing 15uglmL kanamycin and 10uglmL tetracycline 
(Sigma) and grown overnight. White colonies were subsequently restreaked onto McConkey 
arabinose plates as described above. Transfer of the FEI 64 F' episome to BW27786 was 
verified by choosing white colonies, performing colony PCR, as described below, to amplify an 
-2.6kB region of the FE164 episome containing the lac promoter and a portion of the IacZgene 
and sequencing the gel purified -2.6kB colony PCR product. Strain RP166 was constructed 
using the above methods. Strain RP166 is identical to strain RP164 with the exception that the 
F' episome lac promoter has not been mutated and matches the wild type lac promoter 
sequence. 
2.3) PCR Verification of F' Edsome lac Promoter Sequence 
Approximately half of a white bacterial colony was picked from a McConkey arabinose plate 
and transferred to 50ul of nuclease free H20. This mixture was vortexed, boiled for 5 minutes 
and then centrifuged at 12,000rcf for 5 minutes. Ten microliters of supernatant were used as 
the template DNA for a Taq PCR amplification of an -2.6kB region of the FEI 64 episome 
containing the lac promoter and a portion of the IacZgene using reaction mixtures as above, 
primers OK5 and OK6. The following thermal cycling protocol: 
Denaturation+94C 1 min 
30 cycles3 
94C 30sec 
57C 30sec 
68C 150sec 
Final extensionj68C 7min 
was used. The -2.6kB PCR product was gel purified and the identity of the amplified DNA was 
verified by sequencing with primer OK1 81. 
2.4) Construction of Sinale Chain Protease Plasmid pSCPR 
All nonmutagenic PCR reactions contained: 
-50ng plasmid template 
0.5uL each primer (50uM stock) 
1 uL 10mM dNTP mix (Invitrogen, Carlsbad, CA) 
0.25uL Taq polymerase (5UluL) (Invitrogen) 
5uL 10X PCR Buffer (Invitrogen) 
2.5uL 50mM MgCI2 
Nuclease Free H20 to 50uL 
All QuikChange XL Site Directed Mutagenesis (Stratagene, La Jolla, CA) reactions 
contained: 
-1 0ng plasmid template 
1.25uL each primer (1 00uM stock) 
1 uL dNTP mix 
1 uL Pfu Tubro polymerase (2.5UluL) 
5uL 1 OX Reaction Buffer 
3uL Quik Solution 
Nuclease Free H20 to 50uL 
All PCR, site directed mutagenesis and sequencing primers were from Integrated DNA 
Technologies (Coralville, IA). Restriction enzymes were from New England Biolabs (Beverly, 
MA). 
The E. coli lac promoter was amplified from Litmus 38i (New England Biolabs) with primers 
"LacltSph" and "RitelacNco" using the following cycling protocol: 
Denaturation+94C I min 
30 cycles* 
94C 30 sec 
49C 30sec 
68C 40 sec 
Final extension+68C 7min 
The product was gel purified and digested with enzymes Sphl and Ncol. Plasmid pTrcHis2A 
(Invitrogen) was digested with Sphl and Ncol, dephosphorylated using Antarctic Phosphatase 
(New England Biolabs) and the -2.8kb fragment was gel purified. The digested lac promoter 
PCR product above was ligated into the digested pTrcHis2A backbone at 16C overnight with T4 
DNA Ligase (New England Biolabs). The ligation reaction was transformed into strain RPI 64 
that had been made chemically competent using the Z-comp chemically competent cell 
preparation kit (Zymo Research, Orange, CA) as described below. Cells were plated onto LB 
agar containing 1 % glucose, 100ug/mL carbenecillin (American Bioanalytical, Natick, MA) and 
15uglmL kanamycin (Sigma) and allowed to grow overnight. Plasmid DNA was harvested with 
a QIAGEN (Valencia, CA) miniprep kit after growing transformants overnight in LB media with 
1 % glucose, 1 OOugImL carbenecillin and 15ugImL kanamycin. The lac promoter sequence was 
verified using primers Pbrsqrt and Scprleft to give plasmid pLac. 
The wild type HIV protease gene was amplified from ATCC plasmid 671 17 (American Type 
Culture Collection, Manassas, VA) in two separate reactions using two distinct sets of primers: 
"LthvNco" with "LthfSpehvpr" and "Sperthfhvpr" with "RthvPme" and the following cycling 
protocol: 
Denaturation+94C I min 
30 cycles+ 
94C 30 sec 
49C 30sec 
68C 55 sec 
Final extension+68C 7min 
PCR products were gel purified and digested with Sphl and either Ncol or Pmel. The two 
protease PCR products were ligated into the -3.0kB Ncol-Pmel digested, gel-purified pLac 
fragment in a "three piece" ligation reaction and transformed into strain RPI 64. To discourage 
mutation of the protease gene, transformants were plated at 28C and allowed to grow overnight 
and miniprep cultures were grown at 28C. The single chain protease sequence was verified 
using primers "Pbrsqrt" and "Scprleft" to give plasmid pHVP. 
Site-directed mutagenesis to remove the single chain protease glycine residue associated 
with Ncol site was performed using primers "Besttpdlgly" and "Bestbtdlgly". All QuikChange 
reactions were prepared per the manufacturer's instructions and employed the following cycling 
protocol: 
Denaturation+95C 1 min 
18 cycles+95C 50 sec 
60C 50 sec 
68C I I min 
Final extension+68C 1 Omin 
Reaction products were Dpnl digested using the Dpnl included with the QuikChange kit per 
the manufacturer's instructions. Transformation, plasmid harvest and DNA sequencing as 
above yielded plasmid pG2. 
Additional site-directed mutagenesis was performed to create protease gene expression 
promoters stronger than the wild type lac promoter in plasmid pG2. The-35 and-I 0 boxes of 
the tac promoter (DeBoer, 1983) were introduced into the lac promoter using primers 
"TKAtop" and "TKAbot". A second promoter, 38, was constructed via site directed mutagenesis 
of the wild type lac promoter using primers "3581 Otop" and "3581 Obot". Transformation, 
plasmid harvest and sequencing were performed to yield respective tac and 38 promoter single 
chain protease expression plasmids pTKA and p3B. Sequencing of plasmid p3B revealed an 
unanticipated tandem repeat of 50 bases, 
5'-AGGCTTGACACTTTATGCTTCCGGCTCGTATGATGTGTGGAAGTGAGC-3', in the 
promoter region. No action was taken remove these additional 50 bases or to construct a 
replacement for plasmid p3B. 
Site directed mutagenesis with primers "Dn25Top9' and "Dn25Bot3' was performed to 
introduce the inactivating D25N mutation into both subunits of the single chain protease genes 
in the respective pG2, pTKA and p3B plasmids. Transformation, plasmid harvest and 
sequencing were performed to yield respective inactive single chain protease plasmids pLQS1, 
pTQS1 and pB1. 
A subsequent QuikChange site directed mutagenesis reaction to add an Xhol site 
downstream of the Pmel site in plasmid p3B used primers "TpXhoqc" and "QcXhobot". 
Transformation, DNA harvest and sequencing yielded plasmid pSCPR. A plasmid map of 
pSCPR is presented in Figure 1. 
Figure 1. Map of pSCPR single chain HIV protease expression plasmid. 
2.5) Construction of Lamdba Re~ressor Plasmid wl ARA 
The E. coli arabinose repressor (araC) gene and arabinose-controlled expression cassette, 
which consists of a promoter region, cloning site region and terminator region, was amplified 
from plasmid pBAD-TOP0 (Invitrogen) using the Tag PCR reaction mixture as described above 
primers "Pbadtermrite" and "Leftpbdamp" and the following cycling protocol: 
Denaturation+94C 1 min 
30 cycles+ 
94C 30 sec 
49C 30sec 
68C 150sec 
Final extension+68C 7min 
The resulting -1.9kB PCR product was gel purified and digested with Avrll and Hpal. 
Plasmid pCYCDuetl (Novagen, Madison, WI) was digested with Avrll and Hpal. The -2.6kB 
digest fragment was isolated by gel electrophoresis and purified. The 5' phosphate groups were 
removed from the -2.6 kB pCYCDuet1 fragment by reaction with Antarctic Phosphatase (New 
England Biolabs) for 1 hour at 37C using the following reaction mixture: 
1 ug pCYCDuetl -2.6 kB digest fragment 
2uL Antarctic Phosphatase 
7uL 1 OX Antarctic Phosphatase Buffer 
Nuclease Free H20 to 70uL 
The 37C incubation was followed by a 15-minute incubation at 65C to inactivate the 
phosphatase. A 40ul ligation reaction, containing 250ug of the pCYCDuetl digest fragment 
and 200ug of the digested -1.9kB arabinose expression cassette PCR product, was incubated 
at 16C overnight and subsequently transformed into chemically competent RPI 64 cells as 
described below. Cells were plated onto LB agar containing 1 % glucose, 25ug/mL 
chloramphenicol (American Bioanalytical) and 15ug/mL kanamycin and incubated overnight at 
37C. Plasmid DNA was harvested with a QIAGEN miniprep kit after growing transformants 
overnight in LB media with 1% glucose, 25uglmL chloramphenicol and 15uglmL kanamycin at 
37C. The sequence of the inserted arabinose expression cassette was verified using primers 
"Pcyc3800", "Pbadlt" and "Rtpbad" to give plasmid PARA. 
A version of the lambda c l  repressor gene, which has been mutated to create a unique 
Bss.H2 site in the portion of the gene coding for the repressor's flexible linker region, was 
amplified from plasmid pcl .bss (provided by Dr. Tom Kristie, NIH Institute of Viral Diseases, 
Bethesda, MD) using primers "Ncocl It" and "Pmecl rt". The Taq PCR reaction mixture 
described above was used for this amplification. The thermal cycling protocol was also as 
above with the exception that the 30 amplification cycles employed a 70 second 68C extension 
step. The -725bp product was gel purified and digested with Ncol and Pmel. Digested PCR 
product was ligated into the -4.5kB fragment obtained from a Ncol-Pmel digest of plasmid 
PARA at 16C overnight with T4 DNA Ligase. The ligation reaction was transformed into strain 
RP164. Cells were plated onto LB agar containing 1 % glucose, 25ug/mL chloramphenicol and 
15ugImL kanamycin and allowed to grow overnight at 37C. 
Plasmid DNA was harvested with a QIAGEN miniprep kit after growing transformants 
overnight in LB media with 1 % glucose, 25uglmL chloramphenicol and 15uglmL kanamycin at 
37C. The c l  .bss repressor gene sequence was verified using primers "Rtpbad" and "PbadC to 
give plasmid pcl ARABSS. 
The presence of Bss.H2 sites in the araC gene region of the pcl ARABSS plasmid 
necessitated the introduction of a unique cloning site into the flexible linker region of the c l  
repressor. This unique cloning site is for the insertion of oligonucleotide cassettes coding for 
target octamers. A QuikChange site-directed mutagenesis reaction using primers: "Nhecl topn 
and 'Nhebotcl" was performed using the reagent mixture and cycling protocol described above. 
Transformation, DNA harvest and sequencing with primers "Rtpbad" and 'PbadP yielded 
plasmid pcl ARA2Nhe. 
A second QuikChange reaction with primers "Nheqctp" and "Nhebtqc" was performed to 
remove an Nhel site from the P I  5A ori region of plasmid pclARA2Nhe. Transformation, DNA 
harvest, digest with Nhel and agarose gel analysis were used to confirm the presence of a 
single Nhel site, located in the flexible linker region of the c l  repressor gene, to give plasmid 
pcl ARA. A map of plasmid pcl ARA is provided in Figure 2. 
Figure 2. Map of pcl ARA bacteriophage lambda c l  repressor expression plasmid. 
Oligonucleotide cassettes coding for both the Abeta Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp 
(KLVFFAED) octamer and a Cys-Ala-Lys-Lys-lle-Val-Ser-Asp (CAKKIVSD), which is not 
cleaved by the HIV protease (Chou, 1996), were constructed by annealing single-stranded 
oligonucleotides. The respective Abeta and sham oligonucleotide pair sequences: "Abetatop", 
"Botabeta" and "Uncuttop", "Botuncut" were designed so that annealing produces Nhel 
overhangs for ligation into Nhel digested pc1ARA. Oligonucleotides used to make the cassettes 
coding for the other target octamers appearing in Tables 1 and 2 are described above. These 
oligonucleotide cassettes include two glycine codons, GGCGGT, both N- and C-terminal to the 
target octamer codons. Annealing reaction mixtures were as follows: 
6uL each oligonucleotide (1 00uM stock) 
I O l l l  1 OX Annealing Buffer (200mM Tris, pH 7.4,20mM MgCI2, 500mM NaCI) 
Nuclease Free H20 to 100uL 
The following thermal cycling protocol: 
95C 5min 
Ramp from 95C to 25C at .I OCIsec 
25C 30min 
was used to anneal the oligonucleotides into double-stranded oligonucleotide cassettes. 
Double-stranded oligonucleotide cassettes were phosphorylated using T4 Polynucleotide 
kinase (New England Biolabs) by preparing the following reaction mixture: 
0.8ul oligonucleotide cassette reaction mixture 
0.5ul T4 Polynucleotide kinase (1 0 Ulul) 
5 u l 1  OX T4 DNA Ligase buffer 
Nuclease Free H20 to 50uL 
and incubating at 37C for 1 hour. Phosphorylated oligocassettes were subsequently purified 
from the reaction mixture using a Qiagen Nucelotide Cleanup kit. Plasmid pcl ARA was 
digested with Nhel, dephosphorylated with Antarctic Phosphatase and gel purified. Ligation 
reactions, containing 2 0 4  of phosphorylated oligonucleotide cassette and I OOug of Nhel- 
digested pcl ARA in a 20ul reaction volume, were incubated overnight at 16C. The ligation 
reactions were transformed into strain RP164. Cells were plated onto LB agar containing 1 % 
glucose, 25uglmL chloramphenicol and 1 5uglm L kanamycin and allowed to grow overnight at 
Plasmid DNA was harvested with a QIAGEN miniprep kit after growing transformants 
overnight in LB media with 1% glucose, 25uglmL chloramphenicol and 15ugImL kanamycin at 
37C. Oligonucleotide cassette insertion and orientation were verified using primers 'Rtpbad" 
and "Pbadlt". Plasmid pcl AB233 contained two copies of the abeta octamer oligonucleotide 
cassette while plasmid pcl SHAM contained one copy of the uncut CAKKIVSD octamer 
oligonucleotide cassette. 
Respective plasmids pc141 B and pc141B2 contained one and two copies of the phage 
peptide 4B41 Ser-Gly-lle-Phe-Leu-Glu-Thr-Ser (SGIFLGTS) cassette (Beck, 2000). Plasmid 
pcl H I  contained one copy of the HIV genome MAICA site Ser-Gln-Asn-Tyr-Pro-Ile-Val-Gln 
(SQNYPIVQ) cassette. Plasmid pcl HIVMUT contained one copy of the weakly cleaved HIV 
genome MNCA site variant Ser-Gln-Asn-Tyr-Pro-Ile-Gly-Gln (SQNYPIGQ) cassette. 
The HIV genome matrixlcapsid (MNCA) target-containing c l  repressor plasmid, pc14H3, 
was constructed via a different path than pclAB233. A c l  repressor gene, containing an insert 
coding for two copies of the MNCA octamer, Ser-Gln-Asn-Tyr-Pro-Ile-Val-Gln (SQNYPIVQ), 
was amplified from plasmid pcl .HIV-cro (Dr. Tom Kristie, NIH) using the same cycling protocol, 
primers and reaction mixture employed in amplifying the Bss.H2-containing c l  gene from 
plasmid pcl .Bss. The -800bp PCR product was gel purified, digested with Ncol and Pmel and 
ligated into the -4.5kB fragment obtained from the Ncol-Pmel digest of plasmid PARA. 
Six bases, 5'-GCGCGCa', that comprise Bss.H2 sites, are both C-terminal and N-terminal to 
the 24 bases, 5'-AGCCAAAATTACCCTATTGTGCAGG-3', that code for the two MAKA 
(SQNYPIVQ) octamers inserted into the c l  repressor. Twelve bases, 5'-GCTAGCGGTGGC-3', 
that provide an Nhel site followed by two glycine codons, are both C-terminal and N-terminal to 
the 24 bases, 5'-AAGCTGGTGTTCTTGCAGAAGAT-3, that code for the two Abeta 
KLVFFAED octamers. The difference in plasmid sequences between pC14H3 and pC1AB233 
results in the respective MNCA and Abeta insert c l  repressors featuring octameric inserts 
surrounded by different amino acid residues. The additional amino acid residues, relative to the 
wild type c l  repressor, in the MA/CA c l  repressor are Ala-Arg-[SQNYPIVQI-Ala-Arg- 
[SQNYPIVQI-Ala-Arg. The additional amino acid residues in the Abeta c l  repressor are Ala- 
Ser-Gly-Gly-[KLVFFAED]-Gly-Gly-Ala-Ser-Gly-Gly-[KLVFFAED]-Gly-Gly-Ala-Ser. 
A mutation to increase the DNA binding affinity of the c l  repressor protein was introduced 
into Abeta double octamer plasmid pcl AB233 via QuikChange site-directed mutagenesis 
reaction as described above. The Gly48Asn (G48N) c l  repressor mutation was introduced 
using primers "48asntop" and "48asnbot". After transformation and DNA harvest, sequencing 
with primers 'Rtpbad" and 'Pbadlt" was performed to yield plasmid pcl AB233Asn. 
2.6) Protease Random Mutant Librarv Construction 
A single HIV protease subunit was amplified from plasmid 671 17 using primers "Sperthfhvpr" 
and 'RthvXho". The product was gel purified and used as template DNA for random 
mutagenesis of an HIV protease subunit. This subunit was amplified with primers "Sperthfhvpr" 
and "RthvXho" so that digestion with Spel and Xhol would yield an insert for constructing a 
single chain protease library containing randomly mutated C-terminal subunits. Random 
mutagenesis was performed using a Stratagene GeneMorphll Kit. One-half microgram of PCR 
product DNA was used as template for a 200uL mutagenic PCR reaction using primers 
"Sperthfhvpr" and "RthvXho". The following cycling protocol: 
Denaturationj95C 2min 
35 cycles* 
95C 30 sec 
49C 30sec 
72C 60 sec 
Final extensionj72C 1 Omin 
was used. PCR products were gel purified, digested with Spel and Xhol. Approximately 250ng 
of digested PCR product insert were ligated overnight at 16C into approximately 150ng of the 
-3.2kB Spel-Xhol digest fragment of pSCPR in a 60uL reaction. 
2.7) Protease Saturation Mutant Librarv Construction 
Mutant library inserts were created using overlap extension PCR (Ling, 1997) as depicted in 
Figure 3. 
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Figure 3. Overlap extension PCR method diagram (Ling, 1997). 
In the first set of PCR reactions, the -500bp gel purified band from pSCPR, which contains 
the promoter and N-terminal subunit of the single chain protease, was used as a template to 
prevent the generation of a product mixture resulting from primers annealing to both the N and 
C-terminal protease subunits. The first step in overlap extension PCR is to amplify "left" and 
"right" fragments from the respective desired templates. The outer primers (the left primer for 
the "left" fragment and the right primer for the "right" fragment) in these first reactions are 
designed independently of each other and have no sequence homology. The inner primers for 
these first two reactions are designed so that when both fragments are read in the 5 9 3 '  
direction, the "rightn end of the 'left" fragment matches the "left' end of the "right" fragment. The 
"left" and "right" PCR product fragments are gel purified for use as templates in the second step, 
or overlap PCR reaction. 
In the second, or overlap PCR reaction, the "left" and "right" fragments anneal to each other 
in the presence of the outer primers (left-left primer and right-right primer) from the step one 
reactions. The output of this second reaction is a tethered PCR product comprised of both the 
"left" and "right" fragments joined by the matching region of in the middle of the tethered 
product. As one is free to design the overlapping primers as desired, provided that the primers 
bear sufficient homology to the template to anneal properly, overlap extension PCR can be used 
to introduce random mutations at a desired amino acid position by using primers containing a 
mixture of bases at the position(s) to be mutated. It should be noted that as Taq polymerase 
attaches an adenine to the 3' end of approximately 70 percent of the product in a Taq PCR 
reaction, Vent DNA polymerase must be used for overlap extension PCR reactions. 
All first step overlap extension PCR reactions contained: 
-20ng template (restriction digest products subsequently described) 
0.5uL each "inner" and "outer" primer (50uM stock) 
1 uL lOmM dNTP mix (Invitrogen) 
0.3uL Vent Polymerase (2UIuL) (New England Biolabs) 
5uL 1 OX ThermoPol Buffer (NEB) 
Nuclease Free H20 to 50uL 
All first step reactions employed the following cycling protocol: 
Denaturation+94C 1 min 
30 cycles+ 
94C 30 sec 
49C 30sec 
68C 40 sec 
Final extensionj68C 7min 
All second step overlap extension PCR reactions contained: 
-30ng each gel purified left and right step one PCR product templates 
1 uL each "outer" primer (50uM stock) 
2uL 10mM dNTP mix 
0.6uL Vent Polymerase (2UIuL) 
10uL 1 OX ThermoPol Buffer 
Nuclease Free H20 to 100uL 
and employed the following cycling protocol: 
Denaturation+94C 1 min 
33 cycles+ 
94C 30 sec 
42C 30sec 
68C 55 sec 
Final extension368C 7min 
where a reduced annealing temperature is used to ensure proper annealing of the first step 
PCR fragments. It should be noted that first step inner primers should be designed so that the 
step one fragments will have at least 12 overlapping bases. 
For N-terminal saturation mutant library construction, either plasmid pTKA (lac promoter with 
tac -35 and -1 0 boxes) or pG2 (lac promoter) was digested with Spel and Sphl. Both the 
-3.1 kB and -500bp bands were gel purified. The -500bp band, consisting of the protease 
promoter and N-terminal subunit was used as the template in first step PCR reactions. Three 
saturation mutant libraries, with "NNN codons introduced at positions 23-27-28, 28-30-32 and 
47-48-49, were constructed. The primers for the respective left and right fragment first step 
reactions were as follows: 
Left half, outer primer for all: "LacltSph" 
Left half, inner primers: "LeftHf232728Rt", "LeftHf283032Rt9' and "LeftHf474849Rt" 
Right half, outer primer for all: "LtSpehvpr" 
Right half, inner primers: "232728RtHfLeft", "283032RtHfLeft" and "474849RtHfLeft" 
The overlap extension reaction products were digested with Sphl and Spel. Approximately 
250ng of digested PCR product insert were ligated overnight at 16C into approximately 150ng of 
the -3.1 kB Sphl-Spel digest fragment of either pTKA or pG2 (the -3.1 kB fragment is the same 
for both plasmids) in a 60ul reaction. 
Construction of the single chain protease C-terminal subunit D30-Nsubunit D30 saturation 
mutant library required creating two overlap extension PCR step two products. The first product 
was -500bp and was digested with Sphl and Spel. This product was comprised of the protease 
gene promoter from plasmid pSCPR and the N-terminal protease subunit, mutated at residue 
D30. The second product was -300bp and was digested with Spel and Xhol. This product was 
a C-terminal protease subunit mutated at residue D30. These respective overlap extension 
PCR products were gel purified and digested with SphllSpel and SpelIXhol. The digested PCR 
products were subsequently ligated overnight at 16C into the -2.8kB gel purified band from a 
Sphl-Xhol digest of plasmid pSCPR in a three piece ligation reaction. This 60uL ligation 
reaction contained approximately 150ng of the -2.8kB pSCPR digest fragment, -250ng of the 
Sphl-Spel digested N-terminal PCR product and approximately 150ng of the Spel-Xhol digested 
C-terminal PCR product. 
Templates for the first step PCR reactions were obtained by digesting pSCPR with Sphl, 
Spel and Xho I. The three fragments produced were gel purified. The -500bp Sphl-Spel 
fragment was used as the template for the N-terminal subunit step one PCRs while the -300bp 
Spel-Xhol fragment was the template for the C-terminal step one PCRs. PCRs were carried out 
using the cycling protocols and reagent mixtures described above. 
Primers used in the first step reactions for the respective left and right fragment step one 
reactions were as follows: 
Promoter and N-terminal subunit, left half: "LacltSph" and "Lhfbt30" 
Promoter and N-terminal subunit, right half: LL30Rhftop" and "LtSpehvpr" 
C-terminal subunit, left half: "Sperthfhvpr" and "Lhfbt30" 
C-terminal subunit, right half: "3ORhftop" and "Rthvxho" 
Step two, "overlap" PCR reactions were carried out to produce the respective -500bp 
promoter1N-terminal subunit and -300bp C-terminal subunit products using the cycling protocol 
and reagent mixtures described above. Primers used in the step two overlap reactions were as 
follows: 
Promoter and N-terminal subunit: "LacltSph", "ItSpehvpr" 
C-terminal subunit: "Sperthfhvpr", "Rthvxo" 
2.8) Transformation of Z-Comp Competent Cells for Cloninq 
For plasmid transformations, -50ng of plasmid DNA was added to 30uL of Z-comp RP164 
cells and incubated on ice for 1 hour. 1 00uL of pre-warmed 37C SOC media (Invitrogen) were 
then added to the cells and the cells were shaken at 225rpm at 37C for 75 minutes. Sixty 
microliters of cells were plated on LB agar plates with 1 % glucose, 15ugImL kanamycin and 
appropriate antibiotics for plasmid selection. 
For ligation or site-directed mutagenesis reactions, 2uL of ligation reaction, or 1 uL of site- 
directed mutagenesis reaction were added to 50uL of competent RP164 cells and 165uL of pre- 
warmed SOC was added to the cells after incubation with DNA on ice. Prior to plating, cells 
were centrifuged at 3,000 rpm for 7 minutes and resuspended in 65A of room temperature 
SOC. All transformants involving plasmids containing the HIV protease gene were grown 
overnight at 28C to prevent mutation of the protease gene. Transformants with non-protease 
plasmids were grown overnight at 37C. 
2.9) Z-Comp Preparation of Competent Cells for Clonina and Librarv Screening 
A single RPI 64 colony was added to 5mL of LB media with 1 % glucose and 15uglmL 
kanamycin and grown at 37C overnight. SOB media was prepared the day before competent 
cell preparation using the following recipe (per liter): 
59 Yeast Extract 
20g Bacto Tryptone 
0.589 NaCl 
0.5mL 1 M KC1 
150uL 4M NaOH (adjusts pH to -7.0) 
Autoclave 25 minutes 
On the morning of the transformation, the following were added to a baffled 2L shake flask: 
200mL SOB 
2mL 1 M MgCI, 
2mL 1 M MgS04 
350uL overnight cell culture 
120uL 34mglmL kanamycin stock solution 
The flask was shaken at room temperature at approximately 250rpm for -5 hours until cells 
had reached an OD600 of approximately 0.3. Competent cells were prepared per the 
manufacturer's instructions with the modification that cells were frozen at a concentration of 
1 00D60dmL in competent buffer (2 times the concentration recommended by the manufacturer). 
For library screening, the protocol above was followed with a few modifications. An RPI 64 
transformant carrying the Abeta target repressor plasmid, pcl  A8233 was used to inoculate 5mL 
of LB media with 1 % glucose, 20ugImL kanamycin and 25uglmL chloramphenicol from 
American Bioanalytical. To maintain the plasmid during competent cell preparation, 150uL of 
34mglmL stock chloramphenicol in ethanol were added to the 2 liter baffled flask. Cells 
required -6 to 8 hours to reach an ODsrn of 0.3. 
2.1 0) Liquid Culture Betagalactosidase Activitv Assavs 
Plates containing fresh transformants were prepared to inoculate liquid cultures used for 
betagalactosidase activity assays. One microliter of repressor plasmid DNA and either 1.5uL 
Mscl-Xbal plasmid mixture digest reaction or 0.8uL of pure protease plasmid DNA were added 
to 30uL of of thawed Z-comp RP164 cells and allowed to stand on ice for 1 hour. Ninety 
microliters of SOC, prewarmed to 37C, were added and the cells were incubated at 37C with 
shaking at 225rpm for 90 minutes. After shaking at 37C, Eppendorf tubes were centrifuged for 
7 minutes at 2,500rcf. The supernatant was removed and the cell pellet was resuspended in 
60uL SOC. The cell suspension was plated onto LB agar plates containing 1 % glucose, 
7.5*1 o - ~ %  L-arabinose 75uglmL carbenecillin, 25uglmL chloramphenicol and 15ugImL 
kanamycin. Transformants were allowed to grow at room temperature for 18-24 hours. 
Colonies were grown at room temperature to prevent mutation of the single chain protease 
gene. 
Sixteen to twenty hours before carrying out the activity assay, 1 mL of LB media containing 
1 % glucose, 100ugImL carbenecillin, 25uglmL chloramphenicol, 15ugImL kanamycin and 
2*1 o - ~ %  arabinose was added to a 14mL Falcon 2059 roundbottom tube (BD Biosciences, San 
Jose, CA), inoculated with a single colony and incubated at room temperature with shaking at 
225rpm. For each proteaselrepressor combination to be assayed, two separate culture tubes, 
each inoculated with a different colony taken from the same culture plate, were prepared. 
On the morning of the activity assay, tubes containing 1.5mL of the LB media described 
above, prewarmed to 37C, were inoculated with 20uL of the overnight starter culture and 
incubated at 37C with shaking at 225rpm. After 100 minutes, initial culture ODsoo 
measurements were taken. One hundred microliter aliquots of each culture were diluted to a 
total volume of 200uL with LB media in a Falcon 353072 96-well plate (BD Biosciences) and the 
ODeo0 was measured using a Packard Fusion Platereader (Meriden, CT). Upon reaching an 
ODso0 value of approximately 0.6, which usually required between 120 and 160 minutes of 
shaking at 37C, cultures were harvested to prepare extracts for both Pgal activity assays and 
immunoblot validation. Culture ODeo0 values were measured at the time of harvest and the 
values recorded for use in Pgal activity calculations and protein electrophoresis gel loading. 
Cells were lysed using Novagen PopCulture cell lysis reagent to which Novagen (Madison, 
W I) rLysozyme had been added. Lysozyme (30UluL) was diluted 1 :7,500 in lysozyme dilution 
buffer. This lysozyme solution was diluted 1 :I 0 in Novagen PopCulture reagent to give a final 
working rLysozyme concentration of 4UIuL. Eleven microliters of the mixture were dispensed 
into the wells of a 96-well plate. One hundred microliters of each cell culture were added to the 
lysis reagent and mixed gently five times with a multichannel micropipettor. The 96-well plate 
was sealed with Microseal Film (MJ Research, Waltham, MA) to prevent evaporation and 
allowed to rotate at 50rpm at room temperature for 45 minutes. Aliquots of these cell extracts 
were both used in Pgal activity assays and frozen for use in c l  repressor Western blotting. 
Immediately prior to beginning the Pgal assay, a 4mglmL solution containing o-Nitrophenyl- 
beta-D-galactopyranoside (ONPG) in water was thawed and warmed to 28C. The catalytic 
action of betagalactosidase breaks ON PG down into D-galactose and o-nitrophenyl (ON P). 
ONP imparts a yellow color upon the assay buffer. The concentration of ONP can be 
determined by measuring assay buffer absorbance at 415nm. The ONPG solution was diluted 
1 :4.5 into Z Buffer. Betamercaptoethanol (Biorad, Hercules CA) was added to the ONPG-Z 
Buffer mixture at a 1 :61 ratio. One-hundred-and-seventy microliters of the resulting three- 
component mixture were added to the wells of a 96-well plate. Ten microliters of each cell 
lysate to be assayed were added to the 96-well plate and mixed gently five times with a I OuL 
multichannel pipettor. Two assay wells were prepared for each cell extract, thus for a given 
proteaselrepressor combination, 2 replicates for each of 2 culture tubes were obtained, giving 4 
Bgal assay data points per proteaselrepressor combination. 
Immediately after mixing, the 96-well plate was moved into a Spectramax250 Platereader 
(Molecular Devices, Sunnyvale, CA). The platereader was set to read absorbance at 41 5nm 
(ABS415) every 3 minutes for 75 minutes. Microplate chamber temperature was set to 28C. 
Absorbance data were exported to a Microsoft Excel spreadsheet file. The Excel LINEST 
function, which performs linear regression analysis, was used to obtain a linear least squares fit 
value for the slope of ABS,, vs. time. Only timepoints with ABS415 values between 0.1 and 1.0 
were included in the LINEST linear regression analysis. 
As described in Thibodeau (2004), the high-throughput kinetic microplate measurement 
format we employed in obtaining betagal activity values differs from the classic low-throughput, 
tube-based, timed end point betagal assay as described by Miller (1 972). The classic Miller 
Pgal assay employs a spectrophotometer, rather than a microplate reader, to obtain cell culture 
ODsoo values. The Miller assay also employs a spectrophotometer, rather than a microplate 
reader, to measure the color development of the assay buffer containing the E. coli cell lysate 
and the ONPG substrate. Finally, while the kinetic assay does not require that the breakdown 
of the ONPG into o-nitrophenyl (ONP) and D-galactose be halted, the Miller assay calls for the 
addition of Na2C03 to bring about a sudden increase in pH. This pH increase quenches the 
activity of betagalactosidase and allows for end point assay buffer absorbance measurements 
to be made. As the addition of Na2C03 changes the absorbance of the solution, it is necessary 
to account for this difference between the respective kinetic, high-throughput microplate and 
Miller Pgal activity measurement protocols. 
We used the following equation, modified from Thibodeau: 
71' x 1000 x CF1. x CF2 
EletL@T,Tnits = 
A,,, x CF 3 x volume of c ell lys ate per &.ell [~laL] 
to calculate Pgal activity values. This equation accounts for the differences, as described 
above, between the respective kinetic microplate and Miller Pgal activity measurement 
protocols. 
The V variable in the above equation is the slope of reaction buffer ABS415 vs. time as 
calculated by LINEST, for a given microplate well. The Am variable appearing in the above 
equation corresponds to the ODBoo value, measured using the platereader as described above, 
for the cell culture corresponding to the given reaction buffer microplate well. 
Conversion Factor 1 (CFI) converted platereader ABS415 values to spectrophotomer ASS, 
values. Absorbance measurements on dilutions of an o-nitrophenyl (Sigma) solution provided 
the data needed to determine CFI. Regression analysis was used to determine the slope of 
spectrophotomer ABS420 values vs. platereader ABS415 values. This slope was taken as the 
value of CFI . Using an Amersham Ultrospec2100 Pro U N  Vis and the Spectramax250 
platereader, identified above, to obtain the respective ABS4, and ABS415 values gave a CF1 
value of 2.48 +I- 0.05. 
Conversion Factor 2 (CF2) accounted for the deepening of the yellow color of the reaction 
solution that is caused by the addition of Na2C03. Spectrophotometer ABS420 values for 
dilutions of ONP solutions both with and without Na2C03 were made. CF2 is determined by 
performing regression analysis to determine the slope of ABS420(0NP with Na2C03) vs. 
ABS420(0NP only). This analysis yielded a CF2 value of 1.42 +I- 0.05. 
Conversion Factor 3 (CF3) converted the ODBo0 values of the E. coli cell cultures as 
measured by the microplate reader to ODm values as measured using the spectrophotometer. 
Absorbance measurements on dilutions of an E. coli culture provided the data needed to 
determine CF3. Regression analysis was used to determine the slope of spectrophotometer 
ODBoo values vs. platereader ABSm values. This slope was taken as the value of CF3. Our 
analysis gave a CF3 value of 1.8 +I- 0.2. 
As described above, we used 1 O u l ,  or 0.01 mL, of cell lysate per microplate well. As such, a 
value of 0.01 was used as the cell lysate volume term in the denominator of the above pgal unit 
equation. 
Cell extracts for c l  repressor Western blotting were diluted 1 : I  with Laemmli buffer (Biorad) 
containing 1 :20 betamercaptoethanol. These mixtures were placed in a 95C heating block for 5 
minutes and centrifuged at 12,000rcf for 3 minutes. The extract mixtures were divided into 40uL 
aliquots and frozen at -70C. 
The low expression of protease in the absence of IPTG (isopropyl-beta-D- 
thiogalactopyranoside) necessitates that the extract protein concentration be increased above 
that corresponding to the -0.6 OD600 extracts. In the absence of a concentration step, wild type 
protease cell extracts lead to weak bands in protease Western blots and D30 mutant protease 
cell extracts lead to bands that are almost indiscernible. One milliliter of the same -0.6 OD600 
cell culture used to prepare extracts for c l  repressor blotting and Pgal activity assays was 
centrifuged at 2,500rcf for 7 minutes. Culture media was aspirated and the pellet resuspended 
in 300uL of fresh culture media. Preparing a 1 : I6 dilution of the concentrated cell suspension in 
a 96-well plate and measuring with the Fusion Platereader as above provided the ODGoo f the 
concentrated suspension. Cell extracts for Western blotting were prepared by adding 100uL of 
the concentrated cell suspension to the Pop Culture lysis reagent mixture and mixing as above. 
Concentrated cell extracts were diluted with Laemmli buffer and frozen as above. 
Z Buffer recipe (per liter): 
1 6. I g Na2H PO4-7H20 
5.5g NaH2P04-H20 
0.75g KC1 
0.2469 MgS04-7H20 
H20 to 1 liter 
Filter sterilize and store at room temperature 
2.1 1) Protease Mutant Librarv Bluewhite Screeninq 
Eppendorf tubes containing 300uL of Z-comp RPI 64 cells carrying the pCIAB233 Abeta c l  
target repressor plasmid were thawed on ice for 20 minutes and 8uL of the mutant library 
ligation reactions described above were added to the cells. After standing on ice for 1 hour, 
I mL of SOC containing 15/ug/mL chloramphenicol, prewarmed to 37C, was added to the cells. 
Cells were incubated at 37C with shaking at 225rpm for 90 minutes. After shaking at 37C, 
Eppendorf tubes were centrifuged for 7 minutes at 2,500rcf. The supernatant was removed and 
the cell pellet was resuspended in 1.2mL SOC media with 15uglmL chloramphenicol. The 
target plating density of 150-300 colonieslplate was achieved by plating 60uL of cell suspension 
onto each of approximately twenty LB agar plates, prewarmed to 37C, containing 1% glucose, 
7.5*1 04% L-arabinose (Sigma), 1 00ugImL Xgal (5-bromo-4-chloro-3-indolyl-beta-D-galactoside) 
(American Bioanalytical), 75uglmL carbenecillin, 25uglmL chloramphenicol and 15uglmL 
kanamycin. Plates were allowed to develop for 14-1 8 hours at 37C and then allowed to develop 
at room temperature, in the dark, for an additional 3-6 hours. 
Blue colonies were used to inoculate 5mL of LB media containing containing 1 % glucose, 
100ug/mL carbenecillin, 25uglmL chloramphenicol and 15uglmL kanamycin. These miniprep 
cultures were shaken overnight at 225rpm and 28C. Plasmid DNA was harvested and 0.5~9 of 
the isolated pSCPR library clone-pCIARA233 mixture was incubated with Mscl and Xbal, which 
have sites in pCIARA233 but not pSCPR, for 3 hours at 37C in a 25uL reaction volume. A 
subsequent 25-minute incubation at 65C inactivated the restriction enzymes. This restriction 
digest is necessary to ensure that blue phenotypes are not the result of unanticipated 
pC1 ARA233 plasmid behavior. One-and-a-half microliters of the pSCPR-pC1 AB233 digest 
were added to 30uL of pCIARA233-carrying Z-comp RP164 cells. After standing on ice for 1 
hour, 90uL of cells were incubated at 37C with shaking at 225rpm for 90 minutes. After shaking 
at 37C, Eppendorf tubes were centrifuged for 7 minutes at 2,500rcf. The supernatant was 
removed and the cell pellet was resuspended in 60uL SOC containing 15uglmL 
chloramphenicol. Cells were plated onto Xgal-containing bluelwhite screening plates as 
described above. Plates were allowed to develop for 14-1 8 hours at 37C and then allowed to 
develop at room temperature, in the dark, for an additional 1-2 hours. Clones retaining blue 
phenotypes were submitted for DNA sequencing where primers "Pbrsqrt" and "Scprleft" anneal 
to the pSCPR library clone plasmids but not to the pCIAB233 plasmid. 
2.12) Initial Librarv BlueMlhite Screenina with 37C Am~lification and Enrichment 
Initial protease mutant library screenings, which yielded colonies with blue phenotypes but 
did not allow the isolation of homogeneous protease gene sequences, were carried out as 
described above with a small number of modifications. Mutant protease library DNA was 
transformed into E. coli strain RP166. Strain RPI 66 is identical to strain RP164 with the 
exception that the RPI 66 F' episome does not contain -1 0 box lac promoter-weakening 
mutation as described above for RP164. 
Mutant protease libraries were constructed so that protease expression was directed by 
either the tac promoter or the wild type lac promoter. The respective corresponding wild type 
tac and lac promoter plasmids, pTKA and pG2, have been described above. Tac promoter 
libraries were plated onto LB agar plates containing 1 % glucose, 4*10-*% L-arabinose, 20uM 
IPTG, 100uglmL Xgal, 75ugImL carbenecillin, 25uglmL chloramphenicol and 15uglmL 
kanamycin while lac promoter library plates contained 4*1 o - ~ %  arabinose and 200uM IPTG. 
The initial set of library screens was carried out only with the lac promoter saturation mutant 
protease libraries. Only the Ala281Asp30Na132 saturation mutant protease library yielded blue 
colonies after the first round of screening. As such, the Leu23lGly271Ala28 and 
lle47lGly481Gly49 libraries were not further pursued. A bluelwhite screening comparison of the 
lac and tac promoter Ala28lAsp301Va132 saturation mutant protease libraries, subsequently 
described in the Results section, revealed that the tac promoter-based screening protocol was 
better suited to identifying improved protease mutants than the lac promoter based protocol. 
This result motivated further pursuit of only the tac promoter mutant protease library. The 
results of the promoter comparison experiment are subsequently presented in greater detail. 
On the morning after the first round tac promoter Ala28lAsp30Na132 library screening, a 
500mL baffled shake flask containing 100mL of LB media with 1 % glucose, 100ugImL 
carbenecillin, 25uglmL chloramphenicol and l5uglmL kanamycin was inoculated with all of the 
blue colonies from the tac promoter library screening plates. The flask was shaken at 225rpm in 
a 37C incubator until an ODsoo of approximately 0.3 had been reached. An aliquot of cell culture 
was diluted 1 :I with 30% glycerol, divided into cryovials and frozen at -70C. 
Two additional rounds of screening were performed. One milliliter of frozen blue colony 
culture stock was thawed at 37C and diluted into a 250mL baffled flask containing 50mL of LB 
media as described above. Flasks were shaken at 225rpm in a 37C incubator until an ODso0 of 
approximately 0.3 had been reached. Cells were plated onto 15 plates at a density of -200 
colonies per plate. Bluelwhite screening plates were as described above, with the exception 
that the second round screening plates contained 1.0'1 0-'% arabinose while the third round 
screening plates contained 3.0*10-'% arabinose. On the morning following the second round of 
screening, 100 blue colonies were pooled, amplified and frozen. On the morning after the third 
bluelwhite library screening, individual blue colonies were used to inoculate miniprep cultures. 
These miniprep cultures were grown at 37C overnight, with protease plasmid DNA being 
harvested and submitted for sequencing on the following morning. 
DNA sequencing revealed heterogeneous protease gene sequences. As such, liquid culture 
Pgal assays were never carried out using protease plasmid DNA obtained in these initial library 
screens. 
2.1 3) Clone22 Mutant Progeny BlueMlhite Library Screening 
A Clone22 C-terminal random mutant library was constructed as described above, with the 
exception that the C-terminal subunit of Clone22, rather than the C-terminal subunit of the wild 
type protease, was used as the template for mutagenic PCR. Clone22 mutant library DNA was 
transformed into Z-comp RP164 cells carrying the pC1 AB233Asn high affinity Abeta target 
octamer repressor plasmid described above. Transformants were plated onto LB agar plates 
containing 1 % glucose, 6.7*10"% L-arabinose, 100ugImL Xgal, 75uglmL carbenecillin, 25uglmL 
chloramphenicol and 15ugImL kanamycin. 
2.14) Redica Plating Librarv Screeninq 
Protease mutant library DNA was transformed into Z-competent RP164 cells as described 
above. Cells were plated onto LB agar plates containing 1 % glucose, 7.5*1 o -~% arabinose, 
75ugImL carbenecillin, 25uglmL chloramphenicol and 15WmL kanamycin. Plates were 
incubated at 28C overnight. On the morning after transforming library DNA, LB agar plates 
containing 1 % glucose, 7.5*104% arabinose, 100ug/mL Xgal, 20uM IPTG (isopropyl-beta-D- 
thiogalactopyranoside) , 75uglmL carbenecillin, 25uglmL chloramphenicol and 1 5uglmL 
kanamycin were warmed to 37C. A replica plating tool (Bel-Art, Pequannock, NJ) and sterile 
velveteen squares (Sigma catalog#Z363405) were used to transfer colonies from the colony 
source plates to the Xgal containing screening plates. A fresh square was used to transfer each 
source plate. After replica plating, the Xgal containing screening plates were incubated 
overnight at 37C while the source plates were allowed to stand at room temperature overnight. 
On the morning after replica plating, screening plates were examined for blue colonies. A 
small portion of each blue colony was used to inoculate 1.5mL of LB media containing 1% 
glucose, 75ugImL carbenecillin, 25ug/mL chloramphenicol and 15uglmL kanamycin. Culture 
tubes were shaken at 225rpm at 28C until an ODBoo f -0.1 had been reached. This growth 
usually required between 3 and 4 hours. Using disposable plastic inoculating needles (Copan 
Biosciences, Corona, CA), a very small volume of each culture was streaked across a collection 
of 7 Xgal containing (100ug/mL) LB agar plates that had been prewarmed to 37C. This 
collection of 7 plates featured (arabinose, IPTG) concentration pairs as follows: (O%,OuM), 
(6.7*1 o-~%~o), (2*1 0-~%,0uM), (6.7'1 0"%,0~M), (6.7*1 04%,20uM), (6.7*10~~%,50~)), 
(6.7*10~~%,100M)). A range of arabinose and IPTG streak plate concentrations were used to 
allow for discrimination between wild type and candidate mutant colony color. Streak plates 
were incubated at 37C overnight. Source plates from which the culture inoculums were taken 
were stored at 4C. 
On the morning after culture streaking, plates were inspected to identify candidate mutants 
with stronger blue phenotypes than the wild type protease. Miniprep cultures were inoculated 
with colonies taken from source plates stored at 4C. Candidate mutant cultures were grown, 
plasmid DNA harvested, RPI 64 cells re-transformed and Pgal assays carried out as described 
above. 
2.15) Bacteriophage Lambda c l  Repressor lmmunoblottinq 
Cell culture ODGo0 measurements were used to normalize extract loading so that an 
approximately equal amount of total protein was loaded into each well of the gel. Cell extracts 
were thawed on ice and diluted with the following mixture (per mL): 
475uL Laemmli buffer 
455uL LB media 
45uL Novagen Popculture reagent 
25uL Betamercaptoethanol 
so that the final ODsoo of all samples was 0.06. For example, 40uL of an extract prepared from 
a cell culture that had an ODGo0 of 0.6 at the time of harvest would be diluted with 160uL of the 
above mixture. As the extracts are diluted 1:l in Laemmli buffer prior to freezing, the above 5- 
fold dilution reduces the ODsoo of the extract to -0.06. Diluted extracts were placed in a 95C 
heating block for 3 minutes and centrifuged at 12,000rcf for 1 minute. 
Seventeen microliters of diluted extract were loaded into the wells of a 15% TrisHCI, 12-20uL 
comb precast SDS-PAGE minigel (Biorad). BenchMark Prestained (Invitrogen) molecular 
weight standard was diluted 1 : I  with the dilution mixture described above and 17uL loaded into 
one of the wells. This prestained standard was used to monitor electrophoresis and also allows 
one to determine the quality of electrotransfer. BenchMark is not however, visible after 
immunolabeling and imaging the blot. MagicMarkXP (Invitrogen) was diluted 1 :35 with the 
above dilution mixture and 17uL was loaded into one of the wells. This standard is not visible in 
the gel or upon transfer but is bound by secondary antibody HRP-conjugates and thus provides 
a molecular weight standard that can be visualized in immunoblots. 
Gels were run for 70 minutes at 140 volts in a Biorad MiniProtean 2 electrophoresis cell. 
This run time corresponded to the lowest molecular weight (-1 OkD) band of the BenchMark 
PreStained standard being about 2cm from the bottom of the gel. Proteins were transferred 
from the gel to a Biorad lmmunoblot PVDF membrane. Electrotransfer was carried out in a 
Biorad MiniProtean 2 electrophoresis cell for 1 hour at 100 volts. Membranes were blocked in 
TBST (Tris buffered saline with 0.1% Tween 20 [Calbiochem, San Diego, CAI) containing 5% 
nonfat dry milk (NFDM) at 4C overnight. 
All antibody labeling steps were carried out in 20mL of solution. All rinses and washes were 
performed with 50mL of buffer. Prior to primary antibody labeling, membranes were rinsed 
twice in TBST. Dr. J. Beckwith of the Harvard Medical School provided c l  repressor polyclonal 
antiserum from rabbit. This antiserum was diluted 1 :I 0,000 in TBST with 5% NFDM. 
Membranes were incubated with gentle shaking at room temperature for 1 hour. Membranes 
were rinsed twice with TBST and then washed for 15 minutes in TBST prior to secondary 
immunolabeling. Goat anti-rabbit HRP-conjugate (GE Healthcare, Piscataway, NJ) was diluted 
1 :15,000 in TBST. Membranes were incubated with gentle shaking at room temperature for 1 
hour. Membranes were washed 5 times, 5 minutes per wash, in TBST prior to addition of 
Supersignal WestDura HRP Substrate solution (Pierce, Rockford, IL). 
Membranes were imaged using a Biorad Flours flourimager. Images were taken every 
minute for 40 minutes. Repressor bands were quantified using Quantity One imaging software. 
The Volume Rectangle tool was used to draw rectangles of equal area around each c l  
repressor band. The local background subtraction option was enabled. The adjusted volume 
values were recorded. Adjusted volume values are proportional to the total pixel count inside 
the rectangles that the user draws around the bands, minus the pixel background local to a 
given rectangle. The final adjusted volume value is obtained by multiplying this pixel count 
value by the area of the rectangle. Adjusted volume values have units of counts ( c N T ) * ~ ~ ~ .  
The Quantity One software automatically determines the local pixel background. Adjusted 
volume values were taken to be representative of the intensity of the c l  repressor band 
appearing within a given rectangle. 
2.16) HIV Protease lmmunoblottinq 
Concentrated cell culture extract OD600 measurements were used to normalize extract 
loading as above. As discussed in the liquid culture Pgal assay methods section, due to the low 
expression of the HIV protease, extracts prepared from concentrated cell cultures, were used 
for protease immunoblotting. Cell extracts were thawed on ice and diluted with the extract 
dilution mixture described above so that the final of all samples was 0.9. For example, 
40uL of an extract prepared from a cell culture that had been concentrated to an OD60O of 2.3 
would be diluted with 1 1 .1 uL of the extract dilution mixture. As the concentrated extracts are 
diluted 1 :1 in Laemmli buffer prior to freezing, the above dilution reduces the ODcoo of the 
concentrated extract to 0.9. Diluted extracts were placed in a 95C heating block for 3 minutes 
and centrifuged at 12,000rcf for 1 minute. 
SDS-PAGE minigels were loaded as described above and run for 140 minutes at 140 volts in 
a Biorad Miniprotean 2 electrophoresis cell. This run time corresponded to the second lowest 
molecular weight (-1 5kD) band of the BenchMark PreStained standard being at the very bottom 
of the gel. Electrotransfer and membrane blocking were performed as above. 
Prior to primary antibody labeling, membranes were rinsed twice in TBST. Dr. Dave Thomas 
of the NIH AIDS Reagent Program (Germantown, MD) provided anti-HIV protease polyclonal 
antiserum from rabbit. This antiserum was diluted 1 :350 in TBST with 5% NFDM. Membranes 
were incubated with gentle shaking at room temperature for 1 hour. Membranes rinsed twice 
with TBST and then washed for 15 minutes in TBST prior to secondary immunolabeling. Goat 
anti-rabbit HRP-conjugate (GE Healthcare, Piscataway, NJ) was diluted 1 :15,000 in TBST. 
Membranes were incubated with gentle shaking at room temperature for 1 hour. Membranes 
were washed for 5 times, 5 minutes per wash, in TBST prior to addition of Supersignal 
WestDura HRP Substrate solution (Pierce, Rockford, IL). Membranes were imaged and 
protease bands were quantified as described above. 
Dr. Celia Schiffer of the Umass-Worcester Medical School provided the recombinant 
monomeric HIV protease used in the HIV protease antibody blocking experiments. Prior to use, 
an aliquot of this recombinant protease, stored at -70C in buffer containing I OmM Sodium 
acetate [pH 5.51, 10% glycerol, 5% ethylene glycol, 5mM DTT, was thawed and centrifuged for 
10 minutes at 12000rcf in a chilled microfuge. This centrifugation was necessary to remove any 
HIV protease precipitates that may have formed upon thawing. The HIV protease concentration 
in the supernatant was determined by measuring absorbance at 280nm. HIV protease 
supernatant concentrations were approximately 0.5mg HIV proteaselml. Recombinant HIV 
protease was incubated with the HIV protease antiserum in TBST with 5% NFDM at room 
temperature for 30 minutes prior to placing the membrane to be labeled in this solution. 
3. RESULTS 
3.1) Choice of Protease For S~ecificitv Enaineerinq 
We chose to use the HIV protease as a "seed" protease for engineering enzymes with novel 
cleavage specificities. This 99 amino acid aspartic protease enables HIV replication by 
specifically cleaving twelve divergent octameric sequences contained within HIV polypeptide 
precursors (Doherty, 2005). 
The protease functions as a homodimer. The respective monomeric subunits comprising the 
homodimer depicted in Figure 4 have been labeled A and B. The collection of contacts between 
amino acid residues from the respective A and B subunits is referred to as the dimer interface. 
The intersubunit hydrogen bonding, electrostatic interactions and hydrophobic packing of amino 
acid side chains that occur at the dimer interface stabilize the dimeric structure. The residues 
comprising the dimer interface are scattered throughout the entire HIV protease gene. 
Interactions between the C-terminus of subunit "A" and the N-terminus of subunit "B, and vice 
versa, play the greatest role in stabilizing the dimeric structure (Todd, 1998). 
Figure 4. HIV protease dimer crystal structure (Louis, 1998). Key dimer interface residues, 1-5 and 95-99 
from each subunit, are encompassed by rectangle. Substrate binding cleft is encompassed by oval. 
Subunit "A" active site residues are in yellow. Subunit "B" active site residues are purple. 
The homodimeric structure forms a symmetric binding cleft, depicted in Figure 5. This 
symmetric binding cleft accommodates eight asymmetric substrate residues. Previous studies 
have shown that HIV protease is active when expressed in E. coli. (Sices, 1998 and 2001, 
OYLoughlin, 2006). This work has also shown that E. colkbased systems can be used to obtain 
HIV protease mutants with decreased susceptibilities to small molecule protease inhibitors 
(Sices, 1998 and 2001) or with altered cleavage specificities (09Loughlin, 2006). 
Figure 5. HIV protease substrate binding cleft schematic. The residues of the octapeptide substrate are 
numbered, amino-to-carboxyl terminally: P4, P3, P2, PI, PI', P2', P3', P4'. Substrate cleavage occurs 
via hydrolysis of the peptide bond between residues P1 and P1 '. The protease subunits, referred to as 
" A  and "B" in, each contribute four subsites to the binding cleft. The number assigned to each subsite 
matches the number of the substrate sidechain occupying that subsite (Cameron, 1993). " X  denotes 
substrate cleavage point. 
3.2) Protease Specif icitv Enqineerinq Svstem Description 
We have constructed a HIV protease specificity-engineering platform that employs 
betagalactosidase (Pgal) as a reporter gene for protease activity. The employment of Pgal as a 
reporter gene allows for mutant protease libraries to be screened on Xgal containing bluelwhite 
indicator plates. Additionally, use of Pgal as a reporter gene affords quantification of protease 
activity by liquid culture Pgal assay. 
The E. coli RP164 strain and plasmids comprising the protease activity reporter system are 
described in Figure 6. The RPI 64 strain carries an F' episome featuring an E. coli IacZYA 
reporter gene expression cassette immediately downstream of a c l  repressor DNA binding site. 
The lac2 betagalactosidase gene has been deleted from the genome of RP164 to enable the 
use of betagalactosidase as a reporter for HIV protease activity. The lac1 lactose repressor, 
lacy lactose transporter and IacA thiogalactoside acetyltransferase genes have also been 
deleted from the RP164 genome. 
Plasmid pSCPR places single chain HIV protease gene expression under control of the lac 
promoter. The FEI 64 F' episome carried by our E. coli RPI 64 reporter strain features the lacP 
increased quantity lac repressor gene. Although all the standardized library screening and 
protease characterization protocols employ media without IPTG 
(isopropyl-beta-D-thiogalactopyranoside), the lac promoter/repressor combination offers the 
option of IPTG inducible control over protease expression. 
The arabinose operon araBCD and araFGH genes have been deleted from the genome of 
strain RPI 64. Expression of the genomic copy of the araE arabinose transporter gene is under 
the control of a constitutive promoter. The pcl  ARA plasmid places expression of the 
bacteriophage lambda c l  repressor gene under control of the arabinose (pBAD) promoter. 
Plasmid pcl  ARA also provides a copy of the araC arabinose repressor gene. These features 
allow our system to provide well-regulated, arabinose inducible expression of the plasmid borne 
bacteriophage lambda c l  repressor gene (Khlebnikov, 2001 ). 
I 4 . 4  4 . .  . 
, - 
I . .  
. ,  FEIM:" ; L . . 
R E P O R T ~ P I S O M E  
F' :kcZYA operon 
. ; , b lacP . : 
. , 
. . 
. . .  
. . . . 
. . 
E. coli Strain RPl64 
PROTEASE PLASMID 
pBR322 ori#ApRh - 
, . . I . ,  , . 
Figure 6. Protease activity reporter system strain and plasmids. 
The mechanism for reporting HIV protease activity as Pgal activity is depicted in Figure 7. 
The bacteriophage lambda c l  (cl) repressor is capable of binding three distinct 17 base pair 
DNA sequences (Nelson, 1985). The c l  repressor is only able to bind these DNA sequences 
when the protein is in a homodimeric state. The F-prime (F') episome carried by the reporter 
strain features a single c l  repressor DNA binding site. This binding site is upstream of an E. 
coli lac operon expression cassette that has been inserted into the reporter strain's F' episome. 
This repressor binding site will be occupied by the c l  repressor when the cytoplasmic c l  
repressor homodimer concentration is considerably greater than the dissociation constant (Kd) 
of the homodimer for the binding site. Binding site occupation represses expression of the lac 
operon. This lac operon repression results in either white colonies on Xgal-containing 
bluelwhite screening plates or low liquid culture Pgal activity assay values. 
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Figure 7. Mechanism for reporting protease activity. 
The c1 repressor consists of three domains: an N-terminal DNA-binding domain, a C- 
terminal oligomerization domain and a flexible linker domain. The flexible linker domain is both 
tolerant to amino acid insertions and susceptible to proteolysis. Oligonucleotide cassettes, 
coding for HIV protease target octamers, are cloned into the flexible linker domain of the c l  
repressor gene. Each oligonucleotide cassette contains codons for two copies of the target 
octamer. The oligonucleotide cassettes also contain codons that place a series of amino acid 
spacer residues between the two target octamers. When the target octamer-containing c l  
repressors are co-expressed along with the HIV protease, the protease cleaves one of the two 
target octamers that lie within the flexible linker domain. This proteolysis yields c l  repressor 
fragments that cannot form DNA-binding dimers. The resulting decrease in cytoplasmic c l  
repressor DNA-binding homodimer concentration causes the c l  repressor DNA-binding site on 
the reporter strain's F' episome to become unoccupied. Expression of the lac operon cassette 
on the F' episome is subsequently derepressed. Derepression of the lac operon leads to either 
blue colonies on Xgal screening plates or increased liquid culture Pgal assay values. 
Although the HIV protease homodimer's substrate binding cleft is symmetric, the eight 
substrate residues accommodated by this cleft are asymmetric. This "symmetry mismatch" 
suggests that mutant HIV protease heterodimers may realize greater specificity improvements 
than mutant HIV protease homodimers. We have built a construct, pSCPR, which directs the 
expression of single chain HIV protease dimers (scPRs). These scPRs feature respective N- 
and C-terminal HIV protease subunits connected by a flexible Gly-Thr-Ser-Ser-Gly (GTSSG) 
linker. A schematic of the single chain protease gene product is shown in Figure 8. 
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Figure 8. Single chain protease gene product schematic. 
The GTSSG linker codons in plasmid pSCPR contain a unique Spel restriction site. This 
Spel restriction site allows facile construction of mutant scPR heterodimer libraries. The first 
step in creating these scPR heterodimer mutant libraries is the generation of respective mutant 
N- and C-terminal subunit PCR products. Carrying out a three piece ligation reaction to insert 
the N- and C-subunit PCR products into the pSCPR backbone completes mutant scPR 
heterodimer library construction. A plasmid map for pSCPR appears in Figure 1. 
The hypothesized superiority of mutant scPRs, relative to noncovalent mutant HIV protease 
dimers, extends beyond the arena of potential for specificity improvement. Single chain 
proteases are likely to both fold more quickly and be more stable than noncovalent mutant 
protease dimers. These attributes make mutant scPRs more desirable than noncovalent mutant 
HIV protease dimers for the respective applications of inhibiting protein aggregation and 
disrupting viral replication. 
3.3) Arabinose Inducible Control of c l  Repressor Expression 
The liquid culture Pgal assay arabinose titration results of Figure 9 show that the protease 
specificity engineering system allows arabinose inducible, well-regulated control over c l  
repressor expression. An arabinose concentration of approximately 2*1 09% results in c l  
repressor homodimer levels near the Kd value. This 2'1 o - ~ %  arabinose concentration was used 
in subsequent Pgal assays. As subsequently discussed, this well-regulated expression control 
makes the system amenable to octapeptide targets that are cleaved with varying efficiencies by 
the wild type protease. 
Figure 9. Liquid culture Pgal activity assay arabinose titration. Extracts co-expressing wild type protease 
and a c l  repressor containing an octameric insert, Cys-Ala-Lys-Lys-I le-Val-Ser-Asp (CAKKIVSD), which 
is not cleaved by the wild type HIV protease (Chou, 1996). Error bars are determined by multiplying the t- 
value for (n = 2, a = .I) by the standard error measurement for each clone. Assay conditions as 
described in Materials and Methods. 
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3.4) Beta-amvloid Target Octamer ldentif ication 
We sought to determine whether the Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp (KLVFFAED) 
octamer, taken from the Abeta peptide sequence, possessed, as subsequently discussed, the 
desired property of being cleaved by the wild type protease. We made this determination by 
comparing E. coli extract Pgal assay values for cells expressing the active wild type single chain 
protease to Pgal assay values for cells expressing an inactive single chain protease mutant. 
Both subunits of this inactive single chain protease mutant feature Asp+Asn substitutions at 
position 25. As Asp25 is the catalytic Aspartate of the HIV protease, these Asp+Asn 
substitutions yield a single chain protease mutant that has no proteolytic activity. 
We co-transformed the reporter strain with four different protease-repressor expression 
plasmid pairs. The respective protease plasmids allowed expression of the wild type single 
chain protease and the inactive single chain protease mutant described above. One of the 
repressor plasmids directed expression of a c l  repressor containing the matrix capsid (MNCA) 
cleavage site, Ser-Gln-Asn-Tyr-Pro-lle-Val-Gln (SQNYPIVQ), taken from the HIV genome. The 
second repressor plasmid drove the expression of a c l  repressor containing the KLVFFAED 
Abeta octamer. 
The respective active and inactive mutant wild type single chain protease E. coli extract Pgal 
activity values for the MNCA octamer c l  repressor co-transformants are 690 +I- 40 and 260 +/- 
40 Pgal units. The respective active and inactive protease E.coli extract Pgal values for the 
Abeta octamer c l  repressor co-transformants are 370 +I- 40 and 270 +I- 30 Pgal units. Error 
bars are determined by multiplying the t-value for (n = 4, a= .05) by the standard error 
measurement for each clone. These data show that the Abeta KLVFFAED octamer has the 
desired property of being cleaved by the wild type protease. 
The data in Table 1 demonstrate that the protease activity reporter system is capable of 
detecting differences in wild type HIV protease activity toward different octameric target 
sequences. This result foretold the subsequently observed ability of the reporter system to 
detect protease mutants with increased activity, relative to wild type, toward a given target 
octamer. 
Table 1. Effect of target octamer sequence on liquid culture Pgal assay values. Unless noted in 
"Description", cells express active wild type single chain HIV protease. Error bars are determined by 
multiplying the t-value for (n = 2, a = .I) by the standard error measurement for each clone. Assay 
conditions: E. coli strain RP166, protease on lac promoter, LB media with 1 % glucose, 7*10'~% 
arabinose, 15uM IPTG, 100uglmL carbenecillin, 25uglmL chloramphenicol and 15ugImL kanamycin. 
'I '- All c l  repressors used in this study contain a single target octamer 
'2'- Ser-Gln-Asn-Tyr-Pro-Ile-Gly-Gln 
'3'- HIV genome matrixlcapsid site 
'4'- Wild type HIV protease does not cleave SQNYPIVQ octamer with Val to Gly mutation (Kristie, 1998) 
'5'- Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp 
'6'- Ser-Gly-lle-Phe-Leu-Ala-Thr-Ser 
Target lnsertl 
SQNYPIGQ~ 
KLVFFAED~ 
SQNYPIVQ 
SGI FLETS~ 
No Repressor 
SGI FLETS 
Description 
Single Uncleaved MNCA~ variant4 
Abeta Residues 16-23 
Single HIV Genome MNCA Octamer 
Single Phage Library 4B41 Octamer 
No Repressor 
Single 4B41 with Inactive Protease 
BGal Units 
600 +I- 40 
900 +I- 200 
1,500 +I- 300 
2,900 +I- 200 
21,000 +I- 4,000 
530 +I- 30 
3.6) Effect of Target Octamer Multiplicitv on Betagal Reporter Gene Expression 
The data presented in Table 2 show that in the presence of active HIV protease, liquid 
culture Pgal assay values are greater for c l  repressors containing two target octamer inserts 
than for c l  repressors with a single copy of the same target octamer. The Pgal activity values 
for the Asp25Asn inactive mutant protease with respective single and double phage library 
peptide 4841 (Elder, 2000), Ser-Gly-l le-Phe-Leu-Glu-Thr-Ser (SG I FLETS), inserts are 
equivalent. This result indicates that c l  repressor proteolysis, rather than a change in c l  
repressor affinity for its binding site on the F' episome, is responsible for the increased Pgal 
activity values for c l  repressors containing two copies of the target octamer. 
The observation that c l  repressors containing two target octamers are more sensitive to 
proteolytic activity than c l  repressors containing one target octamer motivated the use of a c l  
repressor containing two copies of the Abeta target octamer, Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp 
(KLVFFAED), in mutant protease library screens. Liquid culture Pgal assays used to 
characterize protease specificity employed respective c l  repressors containing double Abeta 
and HIV genome matrixkapsid, Ser-Gln-Asn-Tyr-Pro-Ile-Val-Gln (SQNYPIVQ), target octamer 
inserts. Difficulties in obtaining a double target octamer construct motivated the use of a single 
uncleaved target octamer, Cys-Ala-Lys-Lys-lle-Val-Ser-Asp (CAKKIVSD), as a negative control 
in liquid culture Pgal assays. 
Table 2. Effect of target octamer multiplicity on liquid culture Pgal assay values. Unless noted in 
"Description" column, cells express active wild type single chain HIV protease. Error bars are determined 
by multiplying the t-value for (n = 2, a = .I) by the standard error measurement for each clone. Modified 
assay conditions: E. coli strain RPI 66, protease on lac promoter, LB media with 1 % glucose, 7'1 O-~O/O 
arabinose, 15uM IPTG, 100uglmL carbenecillin, 25uglmL chloramphenicol and 15ugImL kanamycin. 
'a'- Ser-Gln-Asn-Tyr-Pro-I le-Val-Gln 
'b'- HIV genome matrixlcapsid site 
'c'- Wild type HIV protease does not cleave SQNYPIVQ octamer with Val to Gly mutation (Kristie, 1998) 
BGal Units 
1,500 +/- 300 
2,500 +/- 200 
2,900 +/- 200 
7,200 +/- 200 
530 +/- 30 
500 +/- 30 
600 +/- 40 
21,000 +I- 4,000 
Target Insert 
SQNY PIVQa 
(SQNYPIVQ)2 
SGIFLETS 
(SGIFLETS):! 
SG I FLETS 
(SGI FLETS)2 
SQNYPIGQ 
No Repressor 
Description 
Single HIV Genome MNCA~ Octamer 
Double HIV Genome MNCA Octamer 
Single Phage Library 4B41 Octamer 
Double Phage Library 4B41 Octamer 
Single 4841 with Inactive Protease 
Double 4B41 with Inactive Protease 
Single Uncleavedc MNCA Variant 
No Repressor 
Table 3 shows that the addition of 5uM IPTG to liquid culture Pgal assay media increases 
Pgal activity values for proteaselcl repressor combinations in which proteolytic activity is greater 
than background for the zero l PTG case. This outcome is consistent with, as described in the 
"Protease Specificity Engineering System Description" Results section above, IPTG inducible 
control over protease expression. 
Table 3. Effect of protease induction on liquid culture Pgal assay values. Error bars are determined by 
multiplying the t-value for (n = 4, a = .05) by the standard error measurement for each clone. Standard 
assay conditions, as described in Materials and Methods, were used. 
'1'- Matridcapsid octamer double insert: AR-[SQNYPIVQI-AR-[SQNYPIVQI-AR 
'2'- Abeta double insert: ASGG-[KLVFFAEDI-GGASGG-[KLVFFAEDI-GGAS 
'3'- Uncleaved sham single insert: ASGG-[Cys-Ala-Lys-Lys-lie-Val-Ser-Asp]-GGAS 
'4'- Mutant protease (N Subunit Asp30Va1, C Subunit Asp30lle) with increased activity toward KLVFFAED 
'5'- Ser-Gly-lle-Phe-Leu-Ala-Thr-Ser 
Target Octamer 
HIV Genome MAICA' 
 beta^ 
Uncleaved sham3 
HIV Genome MNCA 
Abeta 
Uncleaved Sham 
Abeta 
No Re ressor 
Protease 
Wild Type 
Wild Type 
Wild Type 
Clone 2z4 
Clone 22 
Clone 22 
Inactive 
WildT e 
PGal Units 
No IPTG 
670 +I- 40 
390 +I- 30 
250 +I- 20 
340 +I- 60 
760 +I- 70 
300 +I- 40 
31 0 +I- 30 
12,000 +I- 2,000 
PGal Units 
5uM IPTG 
950 +I- 30 
470 +I- 40 
280 +I- 50 
450 +I- 60 
1,300 +I- 1 00 
300 +I- 70 
370 +I- 30 
3.8) BlueNhite Screening Culture Plate Arabinose Titration 
Figure 10 shows the dependence of colony color upon the concentration of arabinose added 
to the Xgal containing mutant protease library bluelwhite screening plates. This arabinose 
titration, performed with cells transformed with the pTKA (-35 and -10 boxes match tac 
promoter) wild type single chain HIV protease and pcl AB233 Abeta target c l  repressor 
plasmids, shows that the bluelwhite colony color transition occurs at an arabinose concentration 
between 2'1 0"% and 5.5'1 04%. The use of culture plates containing 4'1 0"% arabinose in 
subsequent library screens was motivated by this observation. A similar titration, performed 
with cells transformed with the pG2 (wild type lac promoter, weaker than pTKA) wild type single 
chain HIV protease and pclAB233 identified 4'1 09% as the optimal arabinose concentration for 
lac promoter HIV protease mutant library bluelwhite screens. 
Figure 10. Bluelwhite screening culture plate arabinose titration. Cells co-transformed with wild type HIV 
pTKA protease plasmid and pclAB233 Abeta target c l  repressor plasmid. LB agar plates containing 1 % 
glucose, 20uM IPTG, 100uglmL Xgal, 75uglmL carbenecillin, 25uglmL chloramphenicol and 15ugImL 
kanamycin. Arabinose concentrations as denoted in figure panels. 
3.9) Strategv For Librarv Screening & Construction 
The utility of engineered HIV protease mutants in biomedical applications will be strongly 
dependent upon the ability of these engineered proteases to proteolyze their intended targets 
with a high catalytic rate while not appreciably catalyzing the proteolysis of nontarget proteins. 
One may also present this observation by stating that biomedically useful HIV protease mutants 
will need to possess both increased activity and increased specificity, relative to the wild type 
HIV protease, toward the protein being targeted. Satisfying this criterion requires that increases 
in HIV mutant protease activity toward the intended target be accompanied by relatively smaller 
increases, no change, or preferably, decreases in protease activity toward nontarget proteins. 
This desired combination of mutant protease properties is most readily obtained via a library 
screening method that simultaneously screens for both activity and specificity improvements. 
Alternatively, one could seek to isolate mutants with both improved activity and specificity by 
alternating between activity screens and specificity counterscreens. This screen/counterscreen 
strategy was employed by Varadarajan (2005) to isolate a variant of the OmpT protein, an outer 
membrane endopeptidase of E. coli, with improved activity and specificity toward a peptide 
substrate that is not proteolyzed by the wild type OmpT protein. 
Regardless of whether one is simultaneously screening for activity and specificity or toggling 
between activity screens and specificity counterscreens, one must have the ability to detect 
improvements in mutant protease specificity. Detection of mutant protease specificity 
improvements requires that one identify a component of a given protease's activity profile that 
can serve as a proxy for mutant protease activity toward nontarget proteins. To facilitate 
convenient and reliable detection of specificity improvements, this proxy protease activity 
characteristic should be conducive to both reproducible results and facile comparisons between 
wild type and mutant proteases. Coupling observations of this specificity proxy with 
observations of activity toward the target substrate gives one the ability to make an initial 
evaluation of the mutant protease's utility in the envisioned biomedical application. 
Expression of the wild type HIV protease in the E. colicytoplasm has been observed to be 
cytotoxic to the host cells (Baum, 1990). It is reasonable to interpret this cytotoxicity as the 
result of the proteolysis of an unidentified collection of essential proteins in the E. coli 
cytoplasm. As such, cytotoxicity to the E. coli host cells is a good candidate to serve as a proxy 
for activity toward nontarget proteins in simultaneous activity/specificity screens. Unfortunately, 
observations made during our efforts to develop methods for monitoring protease activity toward 
our substrate of interest, the Abeta KLVFFAED octamer, led us to conclude that a very 
considerable amount of labor would be required to develop protease cytotoxicity-mediated 
screening methods providing reproducible results and facile comparisons between wild type and 
mutant proteases. 
Although we concluded that it would be unwise to pursue the development of a simultaneous 
activity screen/specificity counterscreen method, the possibility of employing Varadarajan's 
(2005) strategy of toggling between activity screens and specificity counterscreens remained 
open. As we considered pursuing the development of a specificity counterscreening method 
however, it occurred to us that we might have been making the mistake of underestimating the 
difficultly in isolating protease mutants with increased activity toward the Abeta target. So as to 
avoid committing this error, we opted to deemphasize specificity counterscreening and focus on 
the challenge of using activity screens to obtain protease mutants with increased activity toward 
the Abeta target. 
Although we chose to focus on isolating mutant proteases with increased activity toward the 
Abeta target, our long term objective of isolating mutant proteases with improved specificity 
toward the Abeta target was unchanged. As such, we sought to develop a convenient method 
for assessing the specificity of any increased activity mutants that might be isolated in our 
mutant protease library activity screens. In the event that our protease activity blue/white 
screens yielded blue phenotype mutant proteases, we planned to validate and quantify the 
apparent activity increases toward the Abeta target via liquid culture Pgal assay. We 
determined that carrying out parallel sets of Pgal assays, allowing us to quantify activity toward 
both the Abeta target and a target serving as a proxy for protease activity toward nontarget 
proteins, would be the most convenient means of assessing mutant protease specificity. 
We had observed that liquid culture Pgal assay measurements of the activity of the wild type 
HIV protease toward the genome matrixlcapsid (MNCA), Ser-Gln-Asn-Tyr-Pro-Ile-Val-Gln, 
target octamer were both reproducible and easy to obtain. Additionally, as robust activity 
toward the MNCA target octamer is an inherent property of the wild type protease, we felt that it 
was reasonable to assume that, for a given mutant protease, increases or decreases in this 
activity would be reflective of increases or decreases in mutant protease cytotoxicity. Our belief 
in the validity of this assumption, combined with our satisfaction regarding Pgal assay 
measurements of protease activity toward the MNCA target, motivated our decision to 
implement mutant protease activity toward the MNCA target as a proxy for activity toward 
nontarget proteins. 
We felt that a review of the literature describing efforts to improve protease activity towards 
uncleaved or weakly cleaved substrates via in vitro directed evolution would be useful in our 
forecasting the properties of the increased activity protease mutants that might be obtained in 
the initial round of bluelwhite screening. We subsequently broadened the scope of our review 
to include papers describing efforts to improve the activity of enzymes toward poor or inactive 
substrates. We found that increased enzyme activity toward a chosen novel substrate is 
generally accompanied by either no change in or increased enzyme inclusiveness toward all 
potential substrates of the enzyme (Aharoni, 2005). 
We have stated above that in improving the specificity of the HIV protease toward a target of 
interest, an increase in protease activity toward the target of interest must be accompanied by a 
relatively smaller increase, no change, or a decrease in protease activity toward nontarget 
proteins. For mutant proteases to be employed in biomedical applications, the ideal case is the 
one in which these proteases possess increased activity toward the chosen target and 
decreased or no activity toward nontarget proteins. The literature motivated us to hypothesize 
that we were unlikely to observe this ideal case. As such, we felt that it would be wise to 
assume that if it proved possible to realize improvements in HIV protease specificity toward the 
Abeta target, these improvements were most likely to be obtained via a combination of 
increased activity toward the Abeta target and either no change in, or a relatively smaller 
increase in protease activity toward nontarget proteins. 
Assuming the mode by which specificity improvements were most likely to be obtained 
allowed us to formulate an appropriate strategy for library construction and screening. This 
strategy could subsequently be modified as warranted by the results obtained. In the context of 
a biomedical application, decreased mutant HIV protease activity toward nontarget proteins, 
relative to the wild type HIV protease, can be realized via one of two avenues. The mutant 
protease can have, on an equal mole basis, reduced activity toward nontarget proteins. 
Alternatively, the mutant protease can have equal or greater mole basis activity toward 
nontarget proteins but be dosed at a concentration sufficiently low to net a decrease in 
nontarget protein cleavage. Our assumption that increased activity toward the Abeta target 
would be accompanied by relatively smaller increases toward nontarget proteins motivated us to 
seek proteases producing reduced cleavage of nontarget proteins, relative to wild type, via the 
second of these two possible avenues. 
We developed a library construction and screening strategy aimed at obtaining specificity 
improvements via multiple rounds of library construction and screening. Each round was 
intended to yield mutant proteases characterized by, relative to the preceding generation of 
proteases, increases in activity toward the Abeta target and either no change, or relatively 
smaller increases in activity toward nontarget proteins. 
We felt that an estimate of the specificity improvement that might be obtained in each round 
of library construction and screening would be useful in our determining how many rounds of 
library construction and screening might be required to yield proteases with potential biomedical 
applicability. Unfortunately, the enzyme specificity improvements obtained via in vitro directed 
evolution, described in the literature (Aharoni, 2005), varied by orders of magnitude. As such, 
we reasoned that it was best to use the low end of the reported improvement range as our guide 
in making a conservative estimate of the size of the specificity improvements that we would 
obtain. The literature motivated our identifying 5- to 10-fold increases in activity toward the 
Abeta target as an appropriately conservative estimate of what could be obtained in each round 
of mutant protease library construction and screening. 
Avoiding unrealistic optimism in estimating activity increases toward the Abeta target 
requires one to favor smaller estimates of increases in activity toward the Abeta target. In 
contrast, avoiding unrealistic optimism in estimating activity increases toward nontarget proteins 
requires one to favor larger estimates of increases in activity toward nontarget proteins. The 
literature suggested that, for any given parent enzyme being engineered for improved specificity 
toward a novel substrate, the progeny mutant with the most greatly improved specificity will 
possess near wild type activity toward the enzyme's native substrate. Given this observation, 
we identified a 2-fold increase in mutant HIV protease activity toward the MA/CA target, our 
chosen proxy for activity toward nontarget proteins, as an activity increase estimate that 
satisfied our criterion of not being overly optimistic. 
After two rounds of library construction and screening, the multiplicative effect of the 
estimated activity increases described above would yield proteases providing 6 to 25 times the 
wild type protease activity toward the Abeta target while providing only a single equivalent of 
wild type protease activity toward nontarget proteins. We felt that the isolation of mutant HIV 
proteases with this improved specificity profile would motivate others to explore the potential for 
employing engineered HIV protease mutants in biomedical applications. As such, we 
developed a strategy for obtaining specificity improvements via two sequential rounds of library 
construction and bluelwhite screening. 
The first round of library screening was intended to identify the protease residues most 
greatly impacting activity toward the Abeta target. We sought to subsequently further improve 
mutant protease activity and specificity by screening second generation libraries in which 
mutations had been targeted to the impactful residue positions identified in the first round of 
library screening. 
While it was our hope that our initial round of bluelwhite mutant library screening would yield 
blue colonies, we realized that it was possible that these initial screens would not identify 
protease mutants with the desired phenotype. Given this possibility, we sought to design the 
initial library screens so that even a negative result would provide useful information. 
So as to facilitate our experimental design, we aimed to identify the most likely causes of a 
negative result. This reflection led us to identify two primary potential causes of failure. 
The employment of a library screening method that was not sufficiently capable of detecting 
increases in protease activity was the first potential cause of failure that we identified. The 
second potential cause of failure that we identified was the possibility that the library being 
screened did not contain any protease mutants with increased activity toward the Abeta target. 
We did not have any "positive control" proteases with greater than wild type activity toward 
the Abeta target. The lack of a positive control protease prevented us from being able to 
perform doping experiments in which the recovery of an improved protease from a wild type 
background validates the library screening method. As such, we entered the library screening 
process with the knowledge that, in the wake of negative results, it may be necessary to modify 
the library screening method. 
A difficult matter to address however, was the point at which one should cease to screen 
additional clones from a given mutant library and instead pursue screening method 
modifications. A satisfactory answer to this question is much more easily obtained when one 
has the knowledge that the mutant library under observation has been exhaustively screened. 
As such, we sought to establish criteria for "exhaustive" screening. We used these criteria to 
guide our design of mutant libraries that could be exhaustively screened within the - lo5 colony 
capacity of our bluelwhite screening protocol. 
We had optimized the arabinose and IPTG concentrations used in bluelwhite mutant library 
screening plates so that all cells transformed with the wild type protease plasmid formed white 
colonies. This optimization made it reasonable to assume that all blue colonies that we might 
encounter in mutant protease library bluelwhite screens were true positives. We defined a true 
positive colony as one that would give rise to blue colonies if the protease plasmid DNA from 
the colony was isolated, retransformed into the reporter strain and replated onto bluelwhite 
screening plates. 
We chose to express the false negative rate in percentage terms. We defined the false 
negative rate as the number of times out of 100 that a cell, transformed with plasmid DNA 
capable of producing a true positive blue phenotype, yielded a white phenotype in bluelwhite 
screening. We believed that if our screening method's false negative rate exceeded 90%, 
modifications to the screening method would be in order. This criterion for method acceptability 
translated to our requiring that, for every ten colonies transformed with a mutant protease 
plasmid capable of reproducibly generating a blue colony phenotype, our screening method 
allow us to isolate at least one blue colony carrying such a mutant protease plasmid. 
We used this false negative rate criterion to establish our definition for "exhaustive" 
screening. As we had specified that we were willing to give the screening method ten chances 
to identify a given mutant protease plasmid as a blue phenotype plasmid, we sought to 
oversample the mutant libraries being screened by a factor of ten. We defined the 
oversampling factor as the number of colonies screened divided by the number of unique amino 
acid sequences that could be translated from a mutant protease plasmid library. If a blue 
phenotype plasmid could not be isolated from a given mutant library after 10-fold oversampling, 
that library would be considered devoid of blue phenotype plasmids. If an exhaustive screen of 
all mutant libraries that we felt warranted screening did not yield any blue phenotype plasmids, 
we would rescreen the mutant protease libraries using a modified method. 
Combining our tenfold oversampling criterion with the library screening capacity of - lo5 set 
our maximum acceptable library size for exhaustive screening at -1 o4 unique mutant protease 
sequences. Our desire to exhaustively screen the mutant libraries that we would be 
constructing ruled out the possibility of our constructing libraries via random mutagenesis. With 
random mutagenesis having been eliminated as mode of library construction, we turned our 
attention to the construction of libraries via targeted mutagenesis. 
Targeted mutagenesis affords one the opportunity to control both the positions within the 
protease gene that are mutated and what residues will be allowed to appear at these positions. 
This control is achieved via design of the primers employed in the mutagenic PCR reactions that 
are used to construct the mutant libraries. We felt that negative results would be more 
conclusive for the case in which all 20 amino acids, rather than a subset of the 20 amino acids, 
were allowed to appear at all positions being mutated. Given this desire to include all 20 amino 
acids and our maximum acceptable library size of -1 04, we defined "X" as the maximum number 
of positions at which mutations can be introduced and solved the expression: 
to find that X 1 3.07. As such, we proceeded to construct libraries containing mutations at three 
positions. 
We sought a rational approach to identifying the residue positions to be mutated. It was our 
desire to target mutations to the HIV protease residue positions that were most likely to 
influence the protease's specificity toward nonnative target substrate sequences. 
We were intrigued by research in which residues comprising the substrate binding cleft of the 
Rous Sarcoma Virus (RSV) protease, a homodimeric protease which is structurally homologous 
to the HIV protease, were mutated (Cameron, 1994). Five RSV protease mutants, each 
carrying a single substitution mutation, were created via targeted mutagenesis. All five of the 
RSV amino acid residues mutated were constituents of the RSV protease's substrate binding 
cleft. These substrate binding cleft residues were mutated to match the amino acids appearing 
in analogous positions on the HIV protease substrate binding cleft. In vitro protease activity 
assays showed that two of the five RSV protease mutants possessed greater than 3-fold activity 
increases, relative to the wild type RSV protease, toward substrates of the HIV protease. This 
"transfer of substrate specificity from the HIV protease to the RSV protease was analogous to 
our objective of altering the substrate specificity of the HIV protease. As such, we felt that 
Cameron's results were ample motivation for our targeting mutations to HIV protease substrate 
binding cleft residues. 
An analysis of HIV protease crystal structures had identified the 17 protease residues 
comprising the substrate binding cleft (Menendez-Arias L, 1994). It should be noted that each 
monomeric protease subunit of the HIV protease dimer contributes 17 residues to the binding 
cleft residues, thus an HIV protease dimer has 34 binding cleft residues. We proceeded to 
construct protease libraries in which mutations, allowing for any of the 20 amino acids to appear 
at the positions being mutated, had been targeted to 3 of the amino acid positions from the pool 
of 17 noted above. Minimization of PCR and cloning labor was our primary objective in 
designing these triple mutant libraries. We identified libraries in which mutations were targeted 
to codons that were close to each other in the single chain protease gene as being the simplest 
to construct. As such, we chose to target mutations to only the N-terminal subunit of the single 
chain protease. We employed overlap extension PCR, as described in Materials and Methods, 
to construct the following three triple mutant libraries. The three respective libraries contained 
mutations at N-terminal subunit positions (Leu23, Gly27,Ala28), (Ala28 ,Asp30, Va132) and 
(I le47, Gly48, G ly49). 
3.10) Saturation Mutant Librarv BlueMlhite Librarv Screeninq 
The methods and strategy underlying the construction of three protease saturation mutant 
libraries have been described above. These libraries were based on the wild type lac promoter 
protease plasmid, pG2. Table 4 shows that one of the three saturation mutant libraries, the 
Ala28lAsp30Na132 (28130132) mutant library, contained blue phenotype clones. 
Table 4. Bluelwhite screening results for N-terminal saturation mutant libraries. Cells co-transformed with 
lac promoter mutant protease plasmid DNA and pcl A8233 Abeta target insert c l  repressor plasmid. LB 
agar plates containing 1 % glucose, 4*1 o -~% arabinose, 200uM IPTG, 1 OOuglmL Xgal, 75ug/mL 
carbenecillin, 25uglmL chloramphenicol and 15uglmL kanamycin. 
The presence of blue phenotype clones in the 28130132 library facilitated an experimental 
determination of whether the lac or tac promoter was better suited to bluelwhite library 
screening. The arabinose titration experiments described above identified the optimal screening 
conditions for both the wild type lac promoter (pG2) and tac promoter (pTKA) wild type single 
chain HIV protease expression plasmids. Table 5 shows that the tac promoter mutant library 
screening plates contained a greater percentage of blue colonies than the' lac promoter library 
plates. 
Residues Mutated 
Leu23, Gly27, Ala28 
Ala28, Asp30, Val32 
lle47, Gly48, Gly49 
Table 5. Bluelwhite screening results for Ala28lAsp30Na132 saturation mutant libraries with both lac and 
tac promoters. Cells co-transformed with mutant protease plasmid DNA and pclAB233 Abeta target 
insert c l  repressor plasmid. All LB agar plates contain 1 % glucose, 100uglmL Xgal, 75uglmL 
carbenecillin, 25ugImL chloramphenicol and 15ugImL kanamycin. Lac promoter plates contain 4'1 o - ~ %  
arabinose and 200uM IPTG. Tac promoter plates contain 4'1 0 ~ ~ 2 %  arabinose and 20uM IPTG. 
Colonies Screened 
-20,000 
-5,000 
-1 0,000 
' I  '- Wild type lac promoter with -35 and -1 0 boxes mutated to match tac promoter (DeBoer, 1983) as 
described in Materials and Methods 
Blue Colonies 
None 
20 
None 
Protease Promoter 
Lac 
Tac' 
Colonies Screened 
-5,000 
-20,000 
Blue Colonies 
20 
330 
% Blue Colonies 
-0.4% 
-1.5% 
These two mutant libraries were constructed using the same mutagenesis method and 
primers. It follows that the mutant populations of these two libraries should be identical. As 
such, one can conclude that the tac promoter allows for more sensitive detection of mutant 
proteases with increased activity than the lac promoter. 
The difference in total protease activity between cells expressing the wild type protease and 
a mutant protease with increased activity toward the Abeta target increases along with the 
concentration of protease in the E. colicytoplasm. The probability that Abeta target c l  
repressor cleavage is sufficient to produce a blue colony phenotype increases with increasing 
total protease activity. These two observations support the hypothesis that the greater 
sensitivity of the tac promoter library screen is the result of the tac promoter being stronger than 
the lac promoter. 
As described in Materials and Methods, after the initial bluelwhite library screen, blue 
colonies from the tac promoter Ala28lAsp30Na132 (28/30/32) library were pooled, amplified and 
frozen. This pool was subsequently thawed, amplified once again and rescreened. Two 
additional rounds of screening were performed, with the screening stringency being increased in 
each of these rounds. Screening stringency increases were achieved by increasing the 
arabinose concentration of the bluelwhite screening plates used by a factor of three in both the 
second and third round screens. 
While all of the colonies taken from the initial library screening plates were deep blue, 
approximately half of the colonies appearing on the second round of screening plates were 
either pale blue or white. Amplifying, freezing, thawing and rescreening only the blue colonies 
from the second round of screening also yielded plates on which approximately half of the 
colonies were either pale blue or white. 
After the third round of screening, plasmid DNA from 12 tac promoter 28130132 library blue 
phenotype clones was harvested and the HIV protease genes were sequenced as described in 
Materials and Methods. Protease gene sequences contained a mixture of bases in the codons 
for protease N-subunit residues 28, 30 and 32. These sequencing observations precluded a 
determination of whether the depletion of blue clones observed after amplification and 
rescreening of the blue colonies chosen from bluelwhite screening plates was due to increased 
screening stringency, loss of protease plasmid heterogeneity within each E. coli cell or a 
combination of these two factors. 
We believed that it was absolutely necessary for our screening system to provide 
unambiguous gene sequences for improved mutant proteases. As such, we sought to develop 
a new screening method that would allow for homogeneous protease gene sequences to be 
derived from cells with blue phenotypes. We had previously observed mutations to the wild type 
HIV protease gene upon sequencing wild type HIV protease constructs that were built during 
development of the protease engineering system. While some wild type protease construct 
colonies yielded minipreps with correct wild type protease gene sequences, others yielded gene 
sequences containing frameshifts, deletions or substitution mutations that produced stop 
codons. 
We were not certain whether the codon 28, 30 and 32 base heterogeneity that we observed 
was the result of in vivo protease gene mutation, transfer of plasmids between E. coli cells 
during the amplify-freeze-thaw-amplify cycles or some combination of these two phenomena. 
As such, we sought to develop a screening method that would address protease gene stability 
and not employ the amplification of cultures inoculated with pooled blue colonies. 
3.12) Redica Plating Method Development 
We observed that E. coli cells transformed with HIV protease expression plasmids grew more 
slowly than cells not carrying HIV protease expression plasmids. Growth rates were reduced 
both in liquid media and on solid media. The reduced growth rates we observed are consistent 
with literature reports of the HIV protease being cytotoxic to E.coli (Baum, 1990). 
HIV protease cytotoxicity complicates the creation of protease expression constructs. As 
stated above, in sequencing various HIV protease expression constructs that we had created, 
we observed protease gene sequences containing frameshifts, deletions or substitution 
mutations that produced stop codons. These undesired alterations in the HIV protease gene 
sequence are the result of in vivo mutation of the protease gene by the E. coli host cell. E. coli 
cells that have mutated the HIV protease expression plasmid to prevent protease expression 
grow more quickly than E. colicells carrying plasmids with unadulterated HIV protease gene 
sequences. After a few generations, this increased growth rate causes the cell population to be 
dominated by cells carrying mutated protease plasmids. This mutant proliferation causes the 
desired construct, containing an unaltered HIV protease gene, to be reduced to an insignificant 
fraction of the plasmid population. 
A common strategy for controlling the in vivo mutation of toxic genes is to perform cloning 
and plasmid amplification under repressing conditions. As our protease expression plasmids 
place protease expression under control of either the lac promoter, or derivatives thereof, we 
sought to maximize repression of protease gene expression by adding 1 % glucose to all media 
used in cloning and plasmid amplification. When coupled with the harvesting and sequencing of 
plasmid DNA from multiple HIV protease plasmid carrying colonies, this strategy allowed for the 
isolation of at least one homogeneous protease plasmid miniprep carrying the correct HIV 
protease gene. In the case of isolating improved mutant proteases however, it is absolutely 
necessary to preserve the correct protease gene sequence corresponding to a given blue 
phenotype clone. As such, we sought a more effective approach for preventing in vivo mutation 
of the HIV protease gene. 
We hypothesized that growing cells at less than 37C would reduce HIV protease cytotoxicity, 
which is the driving force for in vivo mutation of the HIV protease gene, via two mechanisms. 
First, the rate of protein synthesis in E. coli has been observed to be greater at 37C than at 
temperatures less than 37C (Farewell, 1998). As such, growing cells at less than 37C reduces 
the rate at which the HIV protease is synthesized. Secondly, the activity of the HIV protease 
has also been observed to be greater at 37C than at temperatures less than 37C (Elder, 2000). 
Equipment availability motivated our choosing 28C as the temperature for both plasmid 
amplification and for growing transformants plated onto solid media. Growth at this reduced 
temperature prevented mutation of the HIV protease gene expression plasmids. This 
preservation of HIV protease gene integrity demonstrated that the combination of reduced HIV 
protease expression and reduced HIV protease activity had produced the desired effect of 
decreasing the cytotoxicity of the HIV protease to the host E. colicells. 
We observed that bluelwhite screening performed at temperatures less than 37C did not 
allow for bluelwhite discrimination between cells expressing the wild type HIV protease and 
negative control, nil protease cells. This observation necessitated that we develop a library 
screening method that allowed both observation of HIV protease mutant library bluelwhite 
phenotypes at 37C and preservation of the mutant protease genetic information at temperatures 
less than 37C. We identified the established method of replica plating as a protocol that 
satisfied this criterion. 
Figure 1 1  shows the replica plating tool and velveteen squares used in replica plating 
bluelwhite library screens. Mutant protease library DNA transformant colonies were plated onto 
colony source plates and grown overnight at 28C. On the following morning, the replica plating 
tool and squares were used to transfer colonies from the source plates to Xgal-containing 
screening plates. After replica plating, the Xgal containing screening plates were incubated 
overnight at 37C while the source plates were allowed to stand at room temperature overnight. 
Figure 11. Replica plating tool, colony transfer velveteen square and culture plate. 
On the morning after replica plating, screening plates were examined for blue colonies. As 
stated in the "Saturation Mutant Library Bluewhite Screening" section, we sought to employ a 
secondary mutant protease bluelwhite phenotype screen that would not involve the amplification 
of pooled blue phenotype colonies that had been identified in the first round of screening. The 
secondary screening protocol we employed, as described below, satisfied this criterion. 
A small portion of each blue colony was used to inoculate individual liquid cultures. After 
reaching an ODm of -0.1, disposable plastic inoculating needles were used to streak a very 
small volume of each culture onto a collection of Xgal containing bluelwhite screening plates 
with various concentrations of arabinose and IPTG. Streaking cultures onto a range of 
screening plate arabinose and IPTG concentrations allowed for better discrimination between 
wild type and candidate mutant protease activity than streaking onto a single screening plate. 
Streak plates were incubated at 37C overnight. Source plates from which the culture inoculums 
were taken were stored at 4C. 
On the morning after culture streaking, plates were inspected to identify candidate mutants 
with stronger blue phenotypes than the wild type protease. Miniprep cultures were inoculated 
with colonies taken from source plates stored at 4C. Candidate mutant cultures were grown, 
plasmid DNA harvested, reporter strain cells re-transformed and Pgal assays carried out. 
We observed that the E. coli RPI 66 strain did not allow for wild type protease expressing 
cells to display a white phenotype on replica screening plates. Replica plated cells displayed 
strong blue phenotypes regardless of screening plate composition or protease expression 
plasmid promoter. This RPI 66 strain had previously allowed us to achieve a satisfactory 
bluelwhite transition when plating transformants directly onto screening plates. We 
hypothesized that the interplay among protease expression, protease activity, c l  repressor 
expression, Pgal reporter gene expression and hydrolysis of the Xgal color substrate were 
considerably different for the respective situations of a new colony beginning from a single 
transformed E. colicell and a replica colony beginning from an inoculum that had been 
transferred by a velveteen square. Given our inability to obtain HIV protease expression 
colonies with either white or pale blue phenotypes in these initial replica stamping experiments, 
it was clear that this change in interplay among bluelwhite phenotype governing factors would 
require us to explore options for reducing the Pgal reporter gene expression level associated 
with the replica stamping method. 
The F' episome carried by the E. coli RPI 64 reporter strain features a weaker promoter 
upstream of the Pgal reporter gene than does the F' episome carried by the E. coli RPI 66 
reporter strain that was used in the initial replica stamping experiments. We hypothesized that 
the RP164 strain's weaker promoter would allow us to realize our objective of reducing Pgal 
reporter gene expression so as to allow wild type protease1Abeta target repressor plasmid co- 
transformants to display either a white or pale blue phenotype in replica plating screens. 
As shown in the replica plating arabinose titration images of Figure 12, RPI 64 cells co- 
transformed with the pSCPR protease and Abeta insert c l  repressor plasmids display a pale 
blue phenotype when replica plated onto media containing 6.7*10"% arabinose. This result 
confirmed our hypothesis that the RPI 64 strain would allow a satisfactory bluelwhite phenotype 
transition to be realized. We chose to use bluelwhite screening plates containing 7.5*102% 
arabinose in subsequent replica stamping library screens. 
Figure 12. Bluelwhite replica plating arabinose titration. Cells co-transformed with wild type HIV pSCPR 
protease plasmid and pcl AB233 Abeta double insert c l  repressor plasmid. LB agar plates containing 1 % 
glucose, 20uM IPTG, 1 00uglmL Xgal, 75uglmL carbenecillin, 25uglmL chloramphenicol and 1 5uglmL 
kanamycin. Arabinose concentrations as denoted in figure panels. 
3.13) Redica Plate Isolation of Improved Specificitv Mutants 
The replica plating method development experiments described above led us to hypothesize 
that we were in possession of a library screening method that would allow us to isolate the gene 
sequences corresponding to HIV protease mutants with increased activities towards the Abeta 
target octamer. We sought to test this hypothesis by replica plate screening a mutant library 
that was known to contain HIV protease mutants with increased activities towards the Abeta 
target octamer. The results shown in Table 4 identified the Ala28/Asp30Na132 mutant protease 
library as a library satisfying this criterion. 
We sought to use the initial replica stamping library screen as both a validation of the replica 
stamping method and a route to isolate HIV protease mutants with improved specificities toward 
the Abeta target. As discussed in the "Protease Specificity Engineering System Description" 
Results section, we believed that the latter objective was most likely to be realized via screening 
library of proteases containing mutations in both subunits. As such, rather than performing a 
replica stamp screening of the 28/30/32 library, which contained mutations in only the N- 
terminal single chain protease subunit, we opted to construct a new library featuring mutations 
in both the N- and C-terminal protease subunits. 
We desired to construct a library in which the key residue, or residues, responsible for the 
blue phenotypes displayed by a fraction of the mutants in the 28/30/32 mutant protease library, 
would be mutated in both subunits. Additionally, we sought to construct a library with relatively 
small clone diversity. A library with small clone diversity would be readily oversampled. In the 
event that we did not isolate blue phenotype clones from the library, this oversampling would 
allow us to attribute this absence of blue phenotype clones to the quality of the mutants in the 
library, rather than stochastic effects. 
As was the case with our design of the initial libraries to be screened via transformation and 
direct plating onto blue/white screening plates, we believed that our replica plate screening 
library design must account for the replica plating method's false negative rate. As had also 
been the case with the initial direct plating bluelwhite screens, we did not have a "positive 
control" plasmid, coding for a protease with increased activity toward the Abeta target, which 
would permit experimentation to obtain an estimated false negative rate. As such, we opted to 
once again set 90% as the maximum acceptable false negative rate and sought to employ 10- 
fold oversampling in all replica plate library screens. 
Our method development experiments led us to identify -1 o4 as the maximum number of 
colonies that could be expeditiously and reliably screened via replica stamping. Combining this 
upper limit with the 10-fold oversampling criterion set - lo3 as our maximum library diversity. 
For our desired case in which all 20 amino acid possibilities were introduced at each position 
being mutated, a library of 202, or 400, mutants was the largest library that could be 10-fold 
oversampled. As such, we sought to identify a single residue position to be mutated in both 
single chain protease subunits. 
The results shown in Table 4 suggested that mutations at either residue Asp30 or Val32 
were responsible for the blue phenotypes displayed by a fraction of the mutants in the 28/30/32 
N-terminal subunit mutant protease library. We chose to construct and a screen library in which 
we had targeted mutations to both the N- and C-terminal Asp30 residues. We decided to begin 
with a N-terminal30lC-terminal 30 double mutant library with the knowledge that we could 
subsequently construct and screen a Va132Na132 double mutant library in the event that 
proteases with increased activities were not isolated from the 30130 double mutant library. 
We replica stamp screened approximately six thousand 30/30 double mutant library colonies. 
Approximately 10% of these colonies had strong blue phenotypes. We subsequently compared 
150 of these blue phenotype mutant clones to the wild type protease using the bluelwhite 
secondary screening protocol described above. We observed that 25 of these 150 blue 
phenotype mutant clones had greater activity toward the Abeta target than the wild type 
protease. This result suggested that our secondary screening method was relatively stringent 
with respect to identifying mutant proteases with increased activity relative to wild type. 
We also conceived of an alternative hypothesis accounting for the large fraction of 30130 
library mutants that displayed more desirable phenotypes than the wild type protease in the 
initial replica plating screen but were not distinguishable from the wild type protease in the 
secondary screen. This alternative hypothesis was that the replica plating method had a high 
false positive rate. During our method development experiments with the wild type protease, we 
had observed that for plates with sufficient arabinose to produce a pale blue phenotype in the 
majority of the colony population, -1 to 2% of the replica plated colonies had a strong blue 
phenotype. As reported above, -10% of the replica plated 30130 library mutants were blue. A 
comparison of these two percentages suggests that the majority of the 30130 library mutants 
examined in the secondary screen were not first round replica stamping false positives. As 
such, we concluded that the stringency of the secondary library screening method was the 
primary factor underlying the large fraction of 30130 library mutants, identified after replica 
stamping as potentially having increased activity toward the Abeta target, that could not be 
further distinguished from wild type. 
Liquid culture Pgal assays would have provided an alternative metric for determining whether 
any of the 125 30130 library mutants, that were not distinguishable from wild type in the 
secondary screen, were more active toward the Abeta target than the wild type protease. Due 
to the labor involved however, liquid culture Pgal assays are not practical for characterizing 
large numbers of clones. As such, we were willing to accept the high stringency of the 
secondary screening method as the cost of obtaining greater screening capacity than the liquid 
culture Pgal assay was capable of providing. 
We randomly chose 15 of the 25 increased activity clones for plasmid DNA isolation. As 
described in Materials and Methods, we grew miniprep cultures at 28C to prevent in vivo 
mutation of the HIV protease gene. DNA sequencing provided homogeneous sequences for all 
15 clones. Fourteen of these 15 clones had unique sequences. 
We co-transformed protease plasmid DNA for 7 of these 15 clones, along with repressor 
plasmid DNA, into strain RP164. Each mutant protease clone was transformed into RP164 in 
two separate co-transformations. One co-transformation included the pclAB233 Abeta target 
c l  repressor plasmid while the other included the pc14H3 HIV genome matrixkapsid target. 
Liquid culture Pgal assay data for extracts from these co-transformants are shown in Figure 
13. Six of the 30130 double mutant clones: Clones22,41,2/5,2/45,14 and 211 3, posses, 
relative to the wild type protease, both increased Pgal activity toward the Abeta target and 
decreased Pgal activity towards the native MNCA target. These data suggest that these 6 
clones have improved specificity toward the Abeta target. One of the clones taken from the 
30130 double mutant library, Clone57, possesses increased activity toward the Abeta target and 
wild type activity toward the native MNCA target. 
Figure 13. N subunit30-C subunit 30 double mutant library clone liquid culture Pgal assay data. 
Parentheses after clone numbers: (N-terminal subunit residue 30lC-terminal subunit residue 30). 
Clone22 protease activity vs. repressor with sham target = 31 0 +I- 40 Pgal units, wild type protease with 
no repressor = 12,000 +I- 2,000 Pgal units. D25N mutation abolishes protease activity. Error bars are 
determined by multiplying the t-value for (n = 4, a = .05) by the standard error measurement for each 
clone. Abeta target insert: ASGG-KLVFFAED-GGASGG-KLVFFAED-ASGG, Native HIV matrixjcapsid 
site target: AR-SQNYPIVQ-AR-SQNYPIVQ-AR. 
The construction and screening of multiple targeted HIV protease mutant libraries is labor 
intensive. As such, we sought to eliminate the need to employ multiple targeted mutant libraries 
in the initial round of bluelwhile screening. An attractive alternative to the multiple library 
strategy was to construct a random mutant HIV protease library. As shown in Table 13, 
Clone57, an HIV protease mutant obtained in the 30130 double mutant replica plate screening, 
possessed increased activity toward the Abeta target octamer by virtue of a single 
Asp30+Va130 (D30V) mutation in only one of the protease subunits. This improved mutant 
protease represented a "positive controln that could be used to assess the ability of the replica 
plating method to isolate improved mutant proteases in a random library screen. 
We could have doped Clone57 into a wild type background and quantified the percentage of 
doped Clone57 cells that were recovered in a replica plate bluelwhite screening. We felt 
however, that it would be more efficient to proceed directly to the step of addressing whether 
Clone57, or another mutant protease with increased activity, could be isolated from a random 
mutant library. Randomly mutating only the HIV protease C-terminal subunit, while leaving the 
N-terminal subunit as wild type, allowed us to realize our objective of minimizing the PCR and 
cloning labor necessary for library construction. 
Each HIV protease subunit contains 99 amino acid residues. We identified mutagenic PCR 
conditions that produced between 0 and 3 mutations per C-terminal subunit. The D30V 
mutation that was known to yield a mutant protease with increased activity is realized by virtue 
of a single base change (GAT+GTT) in the Asp30 codon. We assumed that all 297 bases in 
the C-terminal subunit were equally susceptible to mutagenesis. We also assumed no bias in 
base mutations. This assumption was in alignment with data provided by the manufacturer of 
the mutagenic PCR kit we used. Given these assumptions, approximately 1 in every 1,000 
members of a random mutant library containing 1 mutation per C-terminal subunit would feature 
the D30V mutation. Combining this estimate with the replica stamp screening capacity of -1 o4 
clones indicated that approximately ten D30V protease mutants should be present in the pool of 
clones examined in a replica plate screening. 
We had set 90% as the maximum acceptable improved activity mutant percentage loss. We 
considered this standard for performance along with the approximately ten D30V clones we 
believed would be present in the library screened. These two considerations motivated our 
employing the ability of the replica plating screening method to isolate a single D30V clone as a 
criterion for determining whether replica plating was a satisfactory method for isolating improved 
mutant proteases from a random library. 
We replica plate bluelwhite screened -1.5'1 o4 transformants from the C-terminal random 
mutant protease library described above. Approximately 2% of the replica plated colonies 
displayed strong blue phenotypes. We chose 100 of these colonies for secondary bluelwhite 
screening. None of these 100 mutant library clones showed improved activity in the secondary 
screening assay. This negative result led us to conclude that replica stamp screening was not a 
satisfactory method for isolating protease mutants with improved activity toward the Abeta target 
from a random mutant library. We proceeded to begin developing an alternative method that 
would allow us to achieve our objective of isolating a D30V mutant, or other improved mutant, 
from the C-terminal random mutant protease library. 
3.14) Protease Mutant BlueMhite Librarv Screening 
We sought to develop a bluelwhite screening protocol that would be capable of isolating a 
D30V mutant, or other mutant protease with increased activity toward the Abeta target, from the 
C-terminal subunit random mutant library described above. Additionally, we desired that this 
protocol not be prohibitively labor intensive. Finally, it was necessary that this method allow 
unambiguous gene sequences to be assigned to the increased activity mutants. 
Our initial protease mutant library screening efforts employed direct plating of E. coli cells, 
transformed with mutant protease library DNA, onto bluelwhite screening plates. This method 
of screening was convenient and also allowed us to identify blue colonies in the first round of 
library screening. Unfortunately, we were unable to isolate homogeneous protease gene 
sequences from the blue colonies. We believed that in vivo mutation, caused by the cytotoxicity 
of the HIV protease to the E. colicells, of the mutant HIV protease genes, had played a major 
role in our inability to resolve mutant protease gene sequences. We also believed that pooling 
blue colonies prior to amplification and rescreening might have contributed to the observed 
protease gene sequence heterogeneity. 
In performing cloning work to construct wild type HIV protease expression plasmids, we had 
observed that growing E. coli transformants and miniprep cultures at 28C had eliminated the 
problem of in vivo HIV protease gene mutation. Experiments to determine the effect of 
temperature on bluelwhite screening had allowed us to conclude that bluelwhite screening was 
not effective at temperatures below 37C. As such, while we were confident that we could 
prevent in vivo mutation during the miniprep culture growth phase, we were concerned that in 
vivo mutation of the HIV protease plasmid may occur during overnight transformant growth on 
bluelwhite screening plates at 37C. We addressed this concern by plating mutant protease 
library transformants onto bluelwhite screening plates lacking IPTG. Applying these conditions, 
which do not induce protease expression, to mutant library screens, minimized the host cell's 
exposure to protease activity. 
We sought a secondary screening method that would not require the pooling of blue colonies 
isolated in the first round of library screening. We also desired that this secondary screening 
protocol allow for mutant protease bluelwhite colony phenotype to be observed under conditions 
identical to those employed in the first round bluelwhite screen. We used blue colonies, isolated 
in the first round of library screening, to inoculate miniprep cultures. Miniprep cultures were 
grown at 28C. We retransformed the plasmid DNA from these miniprep cultures into the 
reporter strain and plated transformants onto bluelwhite screening plates. This secondary 
screening protocol allowed us to both avoid pooling protease library clones and determine the 
reproducibility of bluelwhite colony phenotypes observed in the initial round of library screening. 
Figure 14 shows the sharp bluelwhite color contrast between respective wild type and 
candidate mutant proteases. As described above, protease mutants potentially having 
increased activity towards the Abeta target can be isolated from mutant libraries and validated 
by harvesting plasmid DNA, retransforming and replating on Xgal containing bluelwhite 
screening plates. 
Figure 14. Bluelwhite Xgal culture plate library screening. (a) Wild type protease with Abeta c l  repressor. 
(b) C-terminal random mutant library with c l  Abeta repressor, green circle and arrow denotes candidate 
mutant. (c) Candidate mutant colonies after plasmid harvesting and retransformation with Abeta c l  
repressor. LB agar plates containing 1 % glucose, 7.5'1 o -~% arabinose, 1 OOuglmL Xgal, 75uglmL 
carbenecillin, 25uglmL chloramphenicol and 15uglmL kanamycin. 
The bluelwhite screening method was used to screen a library of -3*104 single chain HIV 
protease mutants in which the C-terminal subunit had been subjected to random mutagenesis. 
Sequencing of library clones picked at random showed that C-terminal subunits contained 
between 0 and 3 mutations. 
Twenty-nine of thirty-six blue "candidate mutant'' colonies retained blue phenotypes after 
DNA harvesting, transformation and bluelwhite assaying. Plasmid DNA for these 29 clones was 
subsequently submitted for sequencing. For all 29 clones, sequencing of the protease gene 
and upstream promoter region provided unambiguous data that allowed protease gene 
sequence resolution. Fifteen of these mutants contained substitution mutations. Thirteen of the 
substitution mutant sequences were unique. Eleven mutants contained silent mutations, with 
two of these sequences being unique. Three clones had protease gene and promoter regions 
matching wild type. 
Liquid culture Pgal assays were performed with cell extracts from 9 of the 13 blue phenotype 
substitution mutants. The assay results, shown in Table 6, identified three mutant proteases 
with increased activity for (n = 4, a= .05) against the Abeta target. The D30V only sequence 
was isolated twice. Two respective D30V mutants containing additional sites of mutation, S37C 
and K45L, were not assayed. 
Table 6. Liquid culture Pgal assay results for random library clones with increased activity against Abeta 
target. Wild type protease with no repressor = 12,000 +I- 2,000 Pgal units, nil protease pBR322 control 
vs. repressor with Abeta target = 290 +I- 20 Pgal units. Error bars are determined by multiplying the t- 
value for (n = 4, a = .05) by the standard error measurement for each clone. Abeta target insert: 
KLVFFAED-GGASGG-KLVFFAED, Native HIV matrixlcapsid site target insert: AR-SQNYPIVQ-AR- 
SQNYPIVQ-AR. 
1 I C Subunit 1 ABeta Target I Native HIV Target / 
/ Clone P7 I D30E. 162L. 164L 1 530 +I- 70 I 700 +/- 200 1 
Protease 
Wild Type 
Clone 211 5 
Clone L2 
Mutations 
None 
D30V 
D30V. 162M 
PGal Assay Units 
330 +I- 70 
700 +/- 70 
800 +I- I00  
PGal Assay Units 
670 +/- 40 
620 +I- 70 
690 +I- 1 10 
Figure 15 provides the pgal assay data obtained for Clone211 5, which was isolated in the C- 
terminal random mutant library screening. Figure 13 also displays the Pgal assay data for the 
30130 double mutant library clones described above. 
Figure 15. Increased activity mutant protease liquid culture Pgal assay data. Parentheses after clone 
numbers: (N-terminal subunit residue 30lC-terminal subunit residue 30). Clone22 protease activity vs. 
repressor with sham target = 31 0 +I- 40 Pgal units, wild type protease with no repressor = 12,000 +/- 
2,000 Pgal units. D25N mutation abolishes HIV protease activity. Error bars are determined by 
multiplying the t-value for (n = 4, a = .05) by the standard error measurement for each clone. Abeta 
target insert: ASGG-KLVFFAED-GGASGG-KLVFFAED-ASGG, Native HIV matrixlcapsid site target: AR- 
SQNYPIVQ-AR-SQNYPIVQ-AR. 
3.15) Clone22 Mutant Proclenv BlueMlhite Librarv Screeninq 
We sought to determine whether additional mutagenesis of the Clone22 protease gene 
would produce progeny with further improvements in activity and/or specificity toward the Abeta 
octamer. Regardless of arabinose concentration, RPI 64 cells co-transformed with respective 
Clone22 protease and Abeta target c l  repressor plasmids displayed a blue phenotype on 
Xgalcontaining bluelwhite screening plates. This observation motivated our constructing a new 
Abeta target c l  repressor plasmid, pcl  AB233Asn. The pcl  AB233Asn repressor plasmid is 
identical to the pclAB233 Abeta target c l  repressor plasmid used in initial mutant protease 
library screens with the exception site directed mutagenesis has been used to change residue 
48 of the Abeta target c l  repressor gene from Glycine to Asparagine. This Gly48Asn mutation 
has been observed to increase the binding affinity of the c l  repressor toward the lambda 
operator DNA sequences (Nelson, 1 985) that it recognizes. 
We used RPI 64 cells co-transformed with respective Clone22 and pcl  AB233Asn plasmids 
in a bluelwhite screening plate arabinose titration. We included Clone22-Abeta target wild type 
c l  repressor co-transformants in this arabinose titration as a control. Cells co-transformed with 
Clone22 and Abeta target wild type c l  repressor plasmids displayed blue phenotypes at all 
arabinose concentrations. Cells co-transformed with Clone22 and Abeta target G48N mutant c l  
repressor plasmids appeared white on all screening plates containing greater than 4.0*1 o - ~ %  
arabinose. The above observations suggested that, as desired, the Abeta target G48N mutant 
c l  repressor bound to the lambda operator DNA binding site, upstream of Pgal reporter gene on 
the RP164 F' episome, with greater affinity than the wild type Abeta target c l  repressor. Cells 
co-transformed with respective Clone22 and pcl  AB233Asn plasmids appeared white on 
screening plates containing 7.5*1 o - ~ %  arabinose. This result, along with the above observation 
of a pale blue phenotype on plates containing 4.0*10-~% arabinose, motivated our using 
7.5'1 0"% arabinose plates in screening Clone22 C-terminal random mutant progeny libraries. 
We screened approximately 2*1 o4 Clone22 C-terminal random mutant progeny library 
clones. All colonies screened displayed white phenotypes identical to that of the parent 
Clone22 control. We elected not to further pursue Clone22 mutant progeny library screening. 
3.1 6) Re~ressor Western Blot Quantification of lm~roved Swcificitv and Activitv 
The c l  repressor bands shown in Figure 16 appear near the anticipated -29kD molecular 
weight. Repressor band quantification reveals that the wild type protease with Abeta target 
extracts contain approximately 2.5-fold more repressor than wild type protease with MNCA 
native target extracts. Clone22 with MNCA target extracts contain approximately 2.5-fold more 
repressor than Clone22 with Abeta extracts. These quantification results are in good agreement 
with the corresponding Pgal activity data presented in Figure 15. These data show that the 
protease activity reporter system functions as depicted in Figure 7. 
The band intensity quantification data, shown in Figure 16, can be used to estimate the 
increase in activity, relative to wild type, towards the Abeta target for the Clone22 cell extracts. 
This estimate is obtained via linear interpolation between the zero protease activity and 
maximum observable activity states. The nil protease pBR322 with Abeta repressor value of 
-22,000 counts is taken as zero activity. The no c l  repressor value of -zero counts is taken as 
maximum observable activity. The wild type protease with Abeta octamer band intensity count 
value is -20,000. This result indicates that the wild type protease cell extracts possess -10% of 
the maximum observable activity towards the Abeta octamer. The Clone22 band intensity count 
value is -7,000. This value suggests that Clone22 cell extracts have -70% of the maximum 
Abeta target activity. A comparison of these two activity estimates implies an approximate 
7-fold increase in activity towards the Abeta target for the Clone22 cell extracts. 
l~rotease Clone22 Clone22 Nil WT Clone22 clone221 
1 Octamer Sham No c l  Abeta Abeta MAlCA Abeta MAlCA I I Counts 23,000 200 22.000 19.800 8.200 6.800 
Figure 16. Western blot for c l  repressor, presented with band quantification and extract bgal assay 
results. Leftmost lane: 30kD molecular weight marker. Lanes 1-7: cell extracts expressing protease and 
repressor clones as denoted in Figure. Sham octamer: uncleaved Cys-Ala-L s-L s-lle-Val-Ser-Asp Y (CAKKIVSD) octamer. "Counts" denotes band intensity data units, CNT*mm , as described in Materials 
and Methods. Primary Antibody: 1 :I 0,000 c l  repressor polyclonal antisera. Secondary antibody: 
1 :15,000 goat a-rabbit HRP conjugate. Betagal assay value error bars are determined by multiplying the 
t-value for (n = 4, a = .05) by the standard error measurement for each clone. 
3.17) Protease Western Blot Validation & Quantification of Improved Specificitv & Activity 
The protease associated bands for both the mutant and wild type single chain protease 
extracts, shown in Figure 17, appear in the -26kD range. The negative control, nil protease 
pBR322 cell extract lanes do not contain bands at -26kD. As the expected molecular weight of 
both the wild type and mutant proteases is -22kD, the above observations suggest that the 
-26kD bands correspond to the proteases migrating to an unanticipated molecular weight. The 
wild type protease extract lanes show a second set of protease-associated bands at -1 8kD. 
These bands may correspond to degraded wild type single chain protease. The -20kD bands 
in both pBR322 nil protease lane 1 and Clone22 lane 10 are not protease species. The band 
intensity quantification data of Figure 15 show that Clone22 and Clone211 5 mutants are present 
in the cell extracts at a two-fourfold lower concentration than the wild type protease. 
MW Monomer 
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Figure 17. Western blot for HIV protease, presented with band quantification results. Lanes 1-3, 5-1 0: 
cell extracts expressing protease and repressor clones as denoted in Figure. Lane 4: molecular weight 
standards. Lane 5: -5ng recombinant monomeric wild type HIV protease. Brown box: Clone211 5 extract 
protease bands. Purple boxes: wild type extract single chain protease bands. Blue boxes: Clone22 
extract protease bands. Magenta boxes: non-protease species bands. "Counts" denotes band intensity 
data units, C N T * ~ ~ ~ ,  as described in Materials and Methods. Primary Antibody: 1 :350 HIV protease 
polyclonal antisera. Secondary antibody: 1,15,000 goat a-rabbit HRP conjugate. 
Table 7 provides estimates of the improvements in Abeta target activity and specificity 
corresponding to Clone22. A given protease's specificity toward the Abeta target is quantified 
by dividing the protease's specific activity against the Abeta target by the protease's specific 
activity against the MNCA target. The respective Abeta:MNCA specific activity ratios for the 
Clone22 and wild type scPRs are 2.9 and 0.1 5. Dividing the Clone22 specific activity ratio by 
the wild type specific activity ratio suggests that the specificity of Clone22 for the Abeta octamer 
is improved approximately 20-fold. The improvement in activity towards the Abeta octamer for 
Clone22 is given by the ratio of Clone22 protease with Abeta c l  repressor and wild type 
protease with Abeta target c l  repressor specific activities. Dividing the Clone22 protease with 
Abeta c l  repressor specific activity of 9.2 by the wild type with Abeta c l  repressor specific 
activity value of 0.32 shows that the activity of Clone22 toward the Abeta octamer is improved 
approximately 30-fold. 
Table 7. Clone22 specificity and activity quantification. "Counts" denotes band intensity data units, 
C N T * ~ ~ ' ,  as described in Materials and Methods. A Repressor denotes nil protease pBR322 with Abeta 
octamer c l  repressor extract c l  band intensity (22,000 counts) minus c l  band intensity (counts) for 
extract denoted in Table 7. Specific activity: A Repressor (counts) divided by protease band intensity 
(counts). Relative specific activity: Specific activity for given extract divided by specific activity value of 
2.2 for wild type protease with MAICA octamer c1 repressor extract. Abeta/[MA/CA] RSA: Specific 
activity for given protease co-expressed with Abeta c l  repressor divided by specific activity for given 
protease co-expressed with MAfCA c l  repressor. 
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3.18) Effect of Taraet Octamer on Protease Expression in the Presence of IPTG 
The HIV protease Western blot of Figure 18 shows that, for Pgal assay cultures grown in 
media containing 5uM IPTG, both the Clone22 and Clone1 4 mutant single chain proteases are 
present at higher concentrations in extracts from E. coli cells co-transformed with the Abeta 
target octamer c l  repressor plasmid than in extracts from cells co-transformed with the HIV 
genome-derived matrix capsid target octamer c l  repressor plasmid. Clone9 is a mutant single 
chain protease, isolated from the 30130 double mutant library, containing an N-terminal 
Asp30Cys mutation and a C-terminal subunit that matches the wild type protease. As noted in 
the Figure 18 caption, in Pgal activity assays with cultures containing 5uM IPTG, Clone9 has 
been observed to have approximately equal activity toward the respective Abeta and 
matrixlcapsid target repressors. As shown in Figure 18, Clone9 band intensity is independent of 
target octamer. Additionally, Clone9 bands are more intense than both the Clone14 and 
Clone22 bands. These Clone9 band properties make Clone9 extracts appropriate standards to 
control for band signal intensity across the blot of Figure 18, where it should be noted that the 
top and bottom panels of Figure 18 have been cut from the same blot. The increased band 
intensity of Clone9, relative to Clone22 and Clonel 4, implies that Clone9 is more stable than 
Clone22 and Clonel 4. 
The F' reporter episome carried by E. colistrain RP164 features the entire lac operon, rather 
than only the betagalactosidase gene, downstream of the c l  repressor DNA binding site. One 
of the three proteins in the lac operon, the lacy lactose permease gene, is a membrane protein 
capable of actively transporting IPTG into the E. colicytoplasm. Both this active transport of 
IPTG and passive diffusion of IPTG across the plasma membrane contribute to the cytoplasmic 
l PTG concentration. 
When Pgal assay culture media does not contain IPTG, IPTG can only enter the cell via 
passive diffusion. Under these conditions, expression of the plasmid borne single chain mutant 
HIV protease gene, which is under control of the lac repressor, is not impacted by lacy 
expression. When cells are grown in the presence of IPTG, the active transport of IPTG into the 
cytoplasm increases with lacy expression. Binding of IPTG to the lac repressor causes the lac 
repressor to take on a conformation that is incapable of repressing protease gene expression. 
As such, in the presence of IPTG, expression of the plasmid borne mutant HIV protease gene 
will increase with increasing lacy expression. By virtue of the lacy gene being expressed along 
with the betagalactosidase reporter gene as described above, lacy expression increases with 
increasing activity of the mutant HIV protease toward the target octamer present in the c l  
repressor. These observations motivate the hypothesis that mutant HIV protease expression 
will be greater in the presence of a c l  repressor containing a target that is highly cleaved than in 
the presence of a c l  repressor containing a target toward which the protease has low activity. 
The data presented in Figure 15 show that, for Pgal assay cultures grown in the absence of 
IPTG, both the Clone22 and Clone14 mutant single chain protease E.coli extracts contain 
greater Pgal activity in the presence of the c l  repressor containing the Abeta target than in the 
presence of the c l  repressor containing the HIV genome matrixlcapsid target. As stated above, 
the HIV protease Western blot of Figure 17 validates that these differences in Pgal activity are 
the result of differences in mutant protease activity toward the two different target octamers, 
rather than differences in mutant protease gene expression levels. These observations allow 
one to apply the hypothesis of the preceding paragraph to the specific cases of Clone22 and 
Clonel4. The outcome of this application is the hypothesis that, for cultures grown in media 
containing IPTG, the expression levels of Clone22 and Clone14 will be greater in the presence 
of the Abeta target c l  repressor than in the presence of the matrix capsid target c l  repressor. 
The HIV protease Western blot of Figure 18 shows that, as hypothesized above, protease 
expression is dependent upon target octamer for cultures grown in media containing IPTG. This 
target octamer dependence of protease expression complicates both immunoblot and Pgal 
assay based comparisons of mutant protease specificity and motivated us to use nil IPTG cell 
extracts in quantifying mutant protease specificity. 
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Figure 18. Western blots for HIV protease in cell extracts from N subunit Asp30-C subunit Asp30 double 
mutant library clone liquid cultures grown in media containing 5uM IPTG. Top panel: Residue 30 double 
mutant protease library clones co-transformed with Abeta target c l  repressor. Bottom panel: Residue 30 
double mutant protease library clones co-transformed with HIV genome matrixlcapsid target c l  repressor. 
Top and bottom panels cut from same blot. Clone22 and Clone14 gene sequences as described in 
Figure 15. Clone9 extracts in rightmost lane shown to control for signal intensity across the blot. Clone9 
contains N-terminal Asp30Cys mutation. Clone9 C-terminal subunit matches wild type. Betagal assay 
value for Clone9 (n = 2, a = .I) with Abeta target: 800 +I- 100 units, with matrix capsid target: 600 +I- 100 
units. Primary Antibody: 1 :I ,000 HIV protease polyclonal antisera. Secondary antibody: 1 ,I 5,000 goat 
a-rabbit HRP conjugate. 
The Western blot of Figure 17 shows bands at -26kD in lanes containing extracts from E. 
colicells expressing the single chain HIV protease. These bands are not present in the nil 
protease control lanes. The absence of these -26kD bands from the Western blot of Figure 15 
led to us to identify the -26kD bands as the single chain HIV protease. 
Figure 17 also shows that there is high background binding of the HIV protease polyclonal 
antisera to non-protease proteins present in the E. coli extracts. Both the protease and 
background bands are absent when the immunoblot membrane is labeled with only secondary 
antibody. Due to the low level at which the E. colicells express the single chain HIV protease, 
the background bands are more intense than the single chain HIV protease bands. This 
nonideal protease:background band intensity ratio motivated us to perform experimentation to 
supplement the protease vs. nil protease extract comparison that we had employed to identify 
the HIV protease bands in the Western blot of Figure 17. 
We sought to identify the single chain HIV protease bands by employing recombinant HIV 
protease as a blocking agent in HIV protease immunoblotting. We added recombinant 
monomeric HIV protease to the primary antibody labeling solution at a molar excess of up to 50 
times our estimated value of the HIV protease antibody concentration. We allowed the HIV 
protease antisera to equilibrate with the recombinant HIV protease prior to exposing the 
immunoblot membrane to the primary antibody labeling solution. We hypothesized this 
equilibration would saturate the antigen binding sites of the HIV protease antibodies. Antigen 
binding site saturation was expected to block the interaction between the HIV protease 
antibodies and the single chain HIV protease molecules contained in the E. coli extracts. A 
resulting reduction in the intensity of the single chain HIV protease bands, but not the 
background bands, would identify the -26kD bands as the single chain HIV protease. 
Figure 19 shows that the intensity of both the -26kD bands and the background bands is 
inversely related to the amount of recombinant HIV protease added to the primary antibody 
labeling solution. This result implies that the antibodies in the polyclonal antisera recognize 
similar epitopes in both the -26kD and the background bands. As this epitope similarity 
precluded our blocking binding to only the -26kD band, we were unable to use the outcome of 
this experiment to supplement the data of Figure 17 in identifying the single chain HIV protease 
band. 
Figure 17. Western blots showing effect of blocking HIV protease antisera with recombinant monomeric 
HIV protease. Amount of HIV protease added to HIV protease polyclonal antisera indicated at top of 
panels. No blocker denotes no recombinant monomeric HIV protease added to HIV protease antisera. 
All three panels cut from same blot. All extracts from cells expressing Abeta target c l  repressor. 
Identical extracts loaded into lanes of each panel, left to right: 113X dilution of wild type HIV protease 
extract, Clone22 extract, nil protease pBR322 extract. Single chain HIV protease migration region 
denoted by rectangles. Primary Antibody: 1 :350 HIV protease polyclonal antisera. Secondary antibody: 
1 ,I 5,000 goat a-rabbit HRP conjugate. 
4. Discussion 
We have demonstrated the potential for our E. coli-based HIV protease specificity 
engineering system to serve as the first general-purpose source of target-specific proteases 
with potential therapeutic applications. This HIV protease specificity engineering system is 
based on a set of established protocols requiring no special equipment, materials or expertise 
and can be readily adopted by any laboratory. This system has enabled the rapid and facile 
isolation of multiple HIV protease mutants with improved specificities and activities toward an 
octapeptide taken from the beta-amyloid peptide (Abeta) implicated in Alzheimer's Disease. In 
addition to having potential as Alzheimer's Disease treatments, target-specific engineered HIV 
protease mutants may find applications in treating Parkinson's Disease, HIV and Hepatitis C. 
Our desire to make the protease specificity engineering system amenable to employment in 
any laboratory motivated our use of the E. coli betagalactosidase protein as a reporter for HIV 
protease activity. The employment of Pgal as a reporter gene allows facile bluelwhite E. coli 
colony screening of mutant protease libraries. Additionally, mutant protease specificity profiles 
are readily assessed via E. coli liquid culture Pgal activity assays. 
So as to give those using our system the opportunity to obtain mutant proteases with 
improved specificities toward whatever target octamer they choose, we sought to make our 
system accommodative of octapeptide targets that are cleaved with varying efficiencies by the 
wild type protease. Additionally, we desired that our system be amenable to the isolation of 
"nth" generation improved specificity mutants via multiple rounds of protease library construction 
and screening. The degrees of freedom associated with the system that we have constructed, 
as summarized in Figure 20, give our system the flexibility needed to satisfy these two criteria. 
As shown in Figure 20, our protease specificity engineering system may be viewed as a 
"black box converter". The mutant proteaseltarget octamer pair associated with a given E. coli 
cell serves as the input signal. Our system converts this input to an easily observed output 
signal. This output signal may be either a bluelwhite screening colony color phenotype or a 
liquid culture bgal assay value. 
Mutant 
Protease BlueiVVhite 
Gene henotype . 
OR 
Target pGal Assay 
Octamer Value 
Arabinose IPTG 
Protease 
Promoter 
I 
Figure 20. Black box representation of protease specificity engineering system. 
Output signal values must lie within a range that allows the detection of input signal 
differences. As such, we desired that, for any given of collection of input signals, our system 
could produce output signals lying within an appropriate range. The "black box" specificity 
engineering system that we have designed satisfies this requirement by providing the user with 
both fine and coarse adjustment knobs. 
The arabinose knob provides fine adjustment and as subsequently described, is key to 
making our system amenable to any octameric target of interest. Betagalactosidase reporter 
gene expression is the result of a balance between the rate at which the wild type or mutant 
protease cleaves c l  repressor molecules in the cytoplasm and the rate at which new c l  
repressor molecules are synthesized. The ability of the screening system to identify improved 
mutant proteases is greatest when the above balance results in cytoplasmic c l  repressor 
homodimer concentrations that are slightly greater than the repressor's Kd for the binding site on 
the F' episome. The wild type protease cleaves different octapeptide targets with varying 
efficiency (Elder, 2000). As such, the ability to achieve maximum sensitivity to increases in 
mutant protease activity for any chosen target octamer necessitates a mechanism for 
well-regulated c l  repressor expression. 
As shown by the liquid culture Pgal assay arabinose titration results of Figure 9, arabinose 
inducible control over c l  repressor expression allows one to identify a culture media arabinose 
concentration corresponding to the c l  repressor homodimer concentration near the maximum 
sensitivity value. Plating of wild type protease-cl repressor plasmid co-transformants onto Xgal 
containing bluelwhite screening plates with varying arabinose concentrations revealed a 
maximum sensitivity arabinose concentration for use in bluelwhite mutant library screening. 
These results suggest that the arabinose knob allows our system to be easily adjusted so as to 
accommodate any octapeptide target, regardless of how efficiently the target is cleaved by the 
wild type protease. 
As described in the Protease Specificity Engineering System Description Results section, our 
system places expression of the plasmid borne single chain HIV protease gene under control of 
a derivative of the lac promoter. This system property offers the user fine adjustment control 
over HIV protease expression via the system's IPTG knob. 
As stated in the Protease Mutant Bluewhite Library Screening Results section, we sought to 
minimize the risk of in vivo mutation of the HIV protease expression plasmid by carrying out 
bluelwhite mutant library screens under the condition of low protease expression. As such, we 
excluded IPTG from the culture plates employed in the blue/white screens described in that 
section. Our exclusion of IPTG from those screening plates does not however, nullify the 
potential utility of the system's IPTG knob. 
As alluded to in the Library Screening Strategy & Construction Results section, one might 
desire to combine blue/white activity screening with a cytotoxicity-mediated specificity 
counterscreen. Our system's fine adjustment control over protease expression, as provided by 
the IPTG knob, would be of considerable utility in developing such a combined activity 
screenlspecificity counterscreen method. This IPTG-mediated control over protease expression 
would allow one to tune such screens for the purpose of identifying conditions under which 
protease expression is sufficient to enable a cytotoxicity-mediated counterscreen but not great 
enough to cause in vivo mutation of the plasmid borne mutant protease gene. 
As stated in the Clone22 Mutant Progeny Bluewhite Library Screening Results section, we 
developed a bluelwhite screening method that allowed us to screen a Clone22 mutant progeny 
library for increased activity, relative to Clone22, toward the Abeta target. The primary 
challenge we encountered in developing this method was that, regardless of arabinose 
concentration, RPI 64 cells co-transformed with the respective Clone22 protease and Abeta 
target wild type DNA-binding affinity c l  repressor plasmids displayed a blue phenotype on Xgal 
containing bluelwhite screening plates. 
In terms of the "black box" view of our protease specificity engineering system, we 
interpreted this inability to obtain a bluelwhite transition as the result of the protease activity 
input signal being too strong to permit output tuning via the arabinose fine adjustment knob. As 
reported in the Clone22 Mutant Progeny Bluewhite Library Screening Results section, we were 
able to obtain a bluelwhite transition by co-transforming the Clone22 protease plasmid with a 
plasmid expressing an Abeta target c l  repressor containing a Gly48Asn mutation that increases 
repressor DNA binding affinity. The success of this coarse adjustment knob resetting 
demonstrates that our system is amenable to increases in mutant protease library screening 
stringency that are greater than what can be achieved via adjustment of culture plate arabinose 
concentration. 
In addition to the repressor coarse control knob, our system also offers one the ability to 
enable screens for improved progeny of second generation mutants, such as Clone22, via 
adjustment of the protease promoter coarse adjustment knob. In the E. coli cytoplasm, the total 
amount of protease activity toward the target of interest is influenced by both the "per mole 
basis" activity of the mutant protease clone toward the given target and the level at which that 
mutant protease is expressed. As such, one can reduce the total protease activity toward the 
target of interest by reducing the level of mutant protease expression. By placing expression of 
the mutant protease gene under control of the wild type lac promoter, rather than the stronger 
lac promoter derivative (38 promoter) employed in the mutant protease plasmid libraries that we 
screened, one can reduce the total protease activity toward the target of interest. This reduction 
in protease activity may allow one to observe a bluelwhite transition for a mutant protease that, 
when expressed from the 38 promoter, possesses a "per mole activity" that does not permit a 
white colony phenotype to be observed. 
The efforts of future protease specificity engineering system users will be facilitated by a 
detailed analysis of our system's performance. This analysis will describe both our successful 
isolation of mutants with improved specificities toward the Abeta target and recently published 
results (O'Laughlin, 2006) describing the identification of an HIV protease mutant with improved 
specificity toward a chosen target substrate. 
We will begin our analysis by discussing the origins of the specificity improvements that we 
have observed. Subsequently, we will compare our findings to those of O'Laughlin (2006) so as 
to facilitate our presentation of avenues by which the performance of our system can be 
improved above its already satisfactory level. Finally, we will provide a detailed description of 
the mechanisms underlying our protease specificity engineering system's behavior. This 
account will assist future users of our system in interpreting phenomena that they might 
otherwise find confusing or disconcerting. 
Protease-peptide crystal structure complexes are useful in explaining the differences in wild 
type and mutant protease activities towards the respective Abeta and MNCA octamers. Figure 
21 features the wild type protease complexed with the HIV genome RHllN peptide, RKILFLDG. 
This image suggests that the reduction in protease activity for the Abeta target peptide relative 
to the MAICA native target peptide is likely to be the result of steric crowding and charge 
repulsion between the Aspartate sidechain at the P4' Abeta peptide position and one of the 
single chain protease D30 sidechains. 
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Figure 21. Image of HIV RNAseHIintegrase junction (L .. I-IN) octapeptide, P4 through P4': Arg-Lys-lle- 
Leu-Phe-Leu-Asp-Gly (RKILFLDG), co-crystallized with HIV protease (Prabu-Jelabayan, 2002). All 
protease residues except Asp30 omitted. Protease subunit one occupies positioned in upper left of view, 
subunit two in lower right. Important difference between RH-IN and Abeta Lys-Leu-Val-Phe-Phe-Ala-Glu- 
Asp (KLVFFAED) octamer, Gly+Asp at P4', noted on image. 
Figure 22 depicts the wild type protease complexed with the MAKA octamer. This figure 
suggests that the loss of either one or both of the hydrogen bonds formed between D30 and the 
respective P2' Asparagine and P4' Serine residues of the MAICA peptide causes the reduced 
activity toward the MNCA octamer, relative to the Abeta octamer, for the double D30, but not 
single D30, protease mutants described in Figure 13. The MNCA octamer is free to dock with 
the protease's substrate binding cleft in either of two orientations. When one of the two wild 
type protease D30 residues is mutated to a smaller residue, the protease-substrate hydrogen 
bonding interactions can still occur for one of the two substrate orientations. When both 
protease D30s are mutated however, the P4'S-D30 sidechain hydrogen bond is certainly lost. 
Additionally, changes in the orientation of the protease backbone relative to the peptide 
substrate may cause the P2'N-D30 backbone carbonyl hydrogen bond to be either lost or 
weakened. 
Figure 22. Image of HIV matrixlcapsid (MAICA) octapeptide, P4+ P4': Ser-Gly-Asn-Tyr-Pro-Ile-Val-Gln 
(SGNYPIVQ), co-crystallized with HIV protease (Prabu-Jelabayan, 2002). All protease residues except 
Asp30 omitted. Protease subunit one occupies positioned in upper left of view, subunit two in lower right. 
Hydrogen bonds between protease subunit two Asp30 and octamer residues Ser(P4) and Asn(P2) noted 
by dashed blue lines on image. 
Table 7 shows that the activity of Clone22 toward the MNCA octamer is greater than the 
activity of the wild type protease toward the MNCA octamer. This result suggests that the 
improvement in Clone22 specificity toward the Abeta octamer stems from Clone22 being more 
inclusive of the Abeta octamer than the wild type protease, rather than from a combination of 
increased Abeta inclusiveness and reduced MA/CA inclusiveness. We hypothesize that the 
increase in activity toward the MAICA octamer is the result of the D30V and D301 mutations 
giving the Clone22 substrate binding cleft a more open structure than the wild type protease 
substrate binding cleft. 
In the Strategy For Library Screening & Construction Results section, we described our 
having forecast that the strategy of screening for increased activity toward the Abeta target, with 
no corresponding counterscreen against activity toward nontarget proteins, was most likely to 
yield improved specificity mutants with increased activity toward the Abeta target and either no 
change in, or a relatively smaller change in, activity toward our proxy for activity toward 
nontarget proteins, the MAICA target octamer. The specificity profile of Clone22 matches the 
mutant protease specificity profile that we had believed was most likely to be obtained. The 
accuracy of our forecast heightened our curiosity regarding the correctness of our hypothesis 
that a combined activity screenlspecificity counterscreen protocol might be capable of yielding 
mutant proteases with increased activity toward the target of interest and decreased activity 
toward nontarget proteins. 
Work recently published by O'Laughlin (2006), aimed at understanding how enzymes adapt 
to utilize novel substrates, has validated our hypothesis regarding the isolation of mutant HIV 
proteases with increased activity toward the target of interest and decreased activity toward 
nontarget proteins. O'Laughlin sought to obtain HIV protease mutants with increased specificity 
toward a peptide sequence taken from the human tumor necrosis factor alpha (TNF-a) protein. 
O'Laughlin employed an E.coli colony color-mediated activity screen/cytotoxicity-mediated 
specificity counterscreen method to examine a library of -6'1 o4 HIV protease mutants. This 
activity screenlspecif icity counterscreen yielded a single HIV protease mutant that possessed 
an -2.5-fold increase in activity toward the TNFa target and displayed no cytotoxicity to the E. 
coli host cells. 
This result validates our hypothesis, as discussed above, regarding the potential to use an 
activity screenlspecificity counterscreen in isolating HIV protease mutants with increased activity 
toward the target of interest and decreased activity toward nontarget proteins. More 
importantly, this result suggests that it may be possible to improve upon Clone22's specificity 
profile by identifying either progeny of Clone22 or new mutants, descended from the wild type 
protease, that have reduced cytotoxicity to the E. coli host cells. 
Our isolating such mutants would require us to develop an activity screen/cytotoxicity 
counterscreen protocol. As stated in the Library Screening Strategy & Construction Results 
section, we had identified the development of such a protocol as being a very labor intensive 
endeavor. Due to the uncertainty regarding our ability to isolate mutant proteases with 
improved activity toward the Abeta target, we chose to focus on activity screening rather than 
undertake the development of an activity screen/cytotoxicity counterscreen protocol. Having 
confirmed that our activity screen is capable of identifying HIV protease mutants with increased 
activity of the Abeta target, the development of a combined activity screen/cytotoxicity-mediated 
counterscreen has now become a logical, albeit challenging, pursuit. The flexibility of our 
protease specificity engineering system, as described in the discussion of Figure 20, would 
facilitate the development of such a combined screen/counterscreen protocol. 
As stated in the Effect of Target Octamer on Protease Expression in the Presence of IPTG 
Results section, expression of the lacy gene increases with increasing protease activity toward 
the target of interest. This relationship must be considered in developing a combined 
screen/counterscreen protocol. In the event that this relationship precluded the development of 
a successful combined screen/counterscreen activity and expression, one might seek to disrupt 
the lacy gene carried on the RPI 64 reporter strain's F' episome via the episomal crossing 
protocol as described by Whipple (1 998). 
Valuable insights regarding the future construction of mutant protease libraries can be 
obtained from a discussion of the mutations identified in 0' Laughlin's improved specificity HIV 
protease mutant. This discussion is best prefaced by a description of 0' Laughlin's HIV 
protease mutant expression system. The HIV protease expression plasmid used by O'Laughlin 
contained a monomeric HIV protease gene. As such, the mutant proteases expressed in 
O'Laughlin's screening system functioned as noncovalent homodimers. This mode of protease 
expression differs from the one employed by our protease specificity engineering system in that 
in our system, mutant proteases are expressed as single chain heterodimers. 
0' Laughlin's HIV protease monomer mutants contained two mutations. One of these 
mutations, Pro9Ser (PgS), corresponds to a dimer interface position. The second mutation, 
Ile50Leu (150L), corresponds to a substrate binding cleft position. Our improved specificity 
single chain protease heterodimer mutants, including Clone22, featured mutations at Asp30, 
which occupies a substrate binding cleft position, in both the N- and C-terminal subunits. 
We have hypothesized, as described above, that the increased activity of Clone22 toward 
the Abeta target is the result of the two Asp30 residues having been mutated to small 
hydrophobic residues. We postulated that these mutations eliminate unfavorable interactions 
between the protease's two Asp30 sidechains and the sidechain of the Aspartate residue 
corresponding to the P4' position of the Abeta substrate. While we hypothesized that Clone22 
owes its improved activity to the deletion of an unfavorable interaction, O'Laughlin stated that 
the increased activity of the P9S150L double mutant (MutantPSSI5OL) toward the TNF-a target 
is likely to be the result of improved interactions between MutantP9SI5OL and the TNF-a target. 
O'Laughlin hypothesized that the 150L mutation contributes to the increased activity of the 
P9S150L double mutant by increasing the hydrophobic interaction between the mutant protease 
and the substrate. 
As discussed above, the respective Clone22 and MutantP9SI5OL binding cleft mutations are 
hypothesized to increase protease activity toward the respective targets of interest via different 
mechanisms. If possible, we would like to employ our recognition and understanding of this 
difference in developing improved strategies for mutant protease library construction. 
Unfortunately, the available data do not allow us to conclude that the elimination of unfavorable 
protease-substrate interactions is superior to the enhancement of favorable protease-substrate 
interactions. As such, we are unable to leverage our binding cleft residue mutation analysis in 
improving mutant protease library construction strategy. In contrast to our binding cleft residue 
mutation analysis, our subsequent analysis of the MutantP9SI5OL dimer interface mutation, 
P9S, yields an interesting approach for improving mutant protease library construction 
strategies. 
O'Laughlin hypothesized that the markedly reduced cytotoxicity of the P9S150L double 
mutant is the result of the P9S dimer interface mutation. This hypothesis was motivated by 
Prabu-Jebelyan's (2000) postulating that the HIV protease's ability to accommodate asymmetric 
substrates, despite the protease being a symmetric homodimer, can be attributed to the ability 
of the dimeric protease to bend itself into an asymmetric form. Prabu-Jebelyan believes that 
this bending allows the HIV protease dimer to alter the topography of its substrate binding cleft 
so as to accommodate the substates that it has evolved to cleave while excluding nontarget 
substrates. 0' Laughlin hypothesized that by changing a residue positioned on the dimer 
interface, the topography of the substrate binding cleft was altered such that the cleft's 
inclusiveness toward nontarget substrates was decreased relative to the wild type HIV protease 
substrate binding cleft. The above observations suggest that targeting mutations to HIV 
protease dimer interface residues may be an effective strategy for increasing the probability of 
isolating HIV protease mutants with reduced cytotoxicity in specificity counterscreens. 
O'Laughlin's protease expression plasmid carries a monomeric HIV protease gene. As such, 
O'Laughlin's MutantP9SI5OL functions as a homodimer. In the "Protease Specificity System 
Description" results section, we hypothesized that heterodimeric single chain protease mutants 
would be more amenable to specificity improvements than homodimeric single chain protease 
mutants. We based this hypothesis on the fact that while a homodimeric single chain protease 
mutant is symmetric, the octameric substrate that it cleaves is asymmetric. Mutant protease 
library construction strategy would be improved by knowing whether the hypothesized superior 
specificity improvement potential of single chain heterodimers, relative to single chain 
homodimers, exists. 
O'Laughlin reported that MutantPSSI5OL, a homodimeric protease, possessed markedly 
improved substrate specificity. This result does not allow one to improve mutant protease 
library construction strategy via either a confirmation or invalidation of the above hypothesis 
regarding specificity improvement potential of the respective heterodimeric and homodimeric 
single chain protease formats. This result does however, allow one to establish an important 
guideline for designing protease libraries containing targeted mutations in both subunits, such 
as the 30-30 double mutant library described in this work. One should be certain that the DNA 
base mixtures employed in the targeted mutagenesis reactions are amenable to the creation of 
all possible homodimeric protease mutants. This outcome can be achieved by considering the 
DNA base mixtures, i.e. G,C,A and T at a given residue position versus G,C and A only, that are 
included in targeted mutagenesis reaction primers. 
We have both thoroughly described the properties of one of our improved specificity mutants 
and identified avenues by which our protease specificity engineering system might be modified 
to yield even more satisfying results in the future. Such future work will most certainly be 
facilitated by the subsequent discussion of the factors underlying our system's performance. 
We sought to obtain specificity improvements via two sequential rounds of library 
construction and bluelwhite screening. Single chain protease random mutant library clones 
contained between 0 and 3 mutations. It follows that the success of our screening strategy was 
dependent upon a small number of mutations being able to produce detectable increases in 
protease activity toward the target octamer. We hypothesized that improving the activity of the 
wild type protease toward an uncleaved target octamer would require more than three protease 
mutations. We also hypothesized that a target octamer for which the wild type protease showed 
a low, but detectable, level of activity in liquid culture pgal assays would allow for protease 
activity to be improved by three or fewer mutations. 
Realizing our objective of obtaining mutant proteases with the potential to function as 
inhibitors of Abeta aggregation required choosing an appropriate target octamer from the Abeta 
peptide sequence. We sought a target octamer that included residues known to be important in 
driving Abeta aggregation. We focused on octamers containing Phel9 because substitutions at 
this residue prevent Abeta oligomerization in vitro (Wood, 1995). Additionally, as discussed 
above, we desired that the wild type protease have detectable activity toward the target 
octamer. We felt that the probability of the wild type protease showing detectable activity 
against randomly chosen octamers was very low. We also hypothesized that the wild type 
protease was likely to have detectable activity toward target octamers bearing homology to at 
least 1 of the 12 octameric substrate sequences in the HIV genome (Doherty, 2005). 
From the set of 8 octamers containing Phel9, we chose the Lys-Leu-Val-Phe-Phe-Ala-Glu- 
Asp (KLVFFAED) octamer, which corresponds to Abeta residues 16-23. This choice was 
motivated by the fact that, as shown in Table 8, KLVFFAED either matches or has primary 
sequence homology to the HIV genome Rnase-lntegrase junction (RH-IN) cleavage site, Arg- 
Lys-lle-Leu-Phe-Leu-Asp-Gly (RKILFLDG), at 6 of 8 positions. Finally, the RKILFLDG peptide- 
HIV protease crystal complex facilitates (Schiffer, 2002) the development of hypotheses for 
explaining improvements in mutant protease specificity and activity. 
Table 8. Comparison of Abeta and RHIIN octameric cleavage sites. Green boxes denote exact residue 
matches at a given octamer position. Orange boxes denote residue homology at a given octamer 
position (i.e. Val at P3 in Abeta and lle at P3 in are both hydrophobic residues, Glu at P3' in Abeta and 
Asp at P3' in RHIIN are both acidic residues). 
Taraet 8mer 1 7 j - -  1 P4' 
PP 16-23 L I D ,  
, RH-IN Site K I G 
As noted in the Protease Mutant BlueMlhite Library Screening Results section, the 
C-terminal random mutant protease library screen led to the isolation of protease plasmids that 
did not contain substitution mutations in the single chain protease gene region. The eleven blue 
phenotype clones with silent mutations were probably the result of these mutations increasing 
mRNA translation via changes in mRNA stability or structure. The three library clone plasmids 
with protease and promoter gene sequences identical to the wild type sequence may contain 
mutations, outside of the protease gene or promoter region, that increase protease expression 
via increased plasmid copy number or alter bluelwhite phenotype manifestation by effecting 
betalactamase expression. 
The migration to unanticipated molecular weights of both the wild type and mutant single 
chain protease bands, shown in Figure 17, may be caused by a high local subunit concentration 
resulting from the genetic linkage between the N-and C-terminal single chain protease subunits. 
A high local subunit concentration may impact gel migration either by preventing complete 
denaturation of the polypeptide chain or by allowing tertiary structure to reform after 
denaturation. The difference in band migration between the respective wild type and mutant 
protease clones may be caused by the fact that mutating the acidic Asp30 residue to a small 
hydrophobic residue in either one, as with Clone2115, or both, as with Clone22, protease 
subunits could impact polypeptide migration by either changing the polypeptide's ionization 
properties or altering the tertiary structure discussed above. 
The reduction in mutant protease band intensity relative to wild type may be the result of the 
Asp30 mutations interfering with correct polypeptide folding during protein synthesis in vivo. 
Replacing an acidic residue with a small hydrophobic residue may either promote translational 
stalling on the E. coli ribosome or lead to unstable mutant protease conformations that are 
degraded in the E. colicytoplasm. Although our tertiary structure-based gel migration 
hypothesis implies that once properly folded, both the mutant and wild type single chain 
proteases are resistant to unfolding, this hypothesis does not preclude the possibility that these 
properly folded structures are realized with differing levels of efficiency. As such, the respective 
unanticipated band migration and band intensity difference hypotheses are compatible with 
each other. 
We are excited by the potential for our E. coli-based mutant protease screening system to 
serve as the first general-purpose source of target-specific proteases with potential therapeutic 
applications. This HIV protease specificity engineering system is based on a set of established 
protocols requiring no special materials or expertise and can be readily adopted by any 
laboratory. This system is amenable to a wide range of target substrate sequences. The 
system also provides facile control over the stringency employed in mutant protease library 
screening. Additional method development work may allow future users to improve the already 
satisfactory performance of this system. 
We have identified Alzheimer's Disease, Parkinson's Disease, HIV and Hepatitis C as 
maladies that may be treated with target-specific proteases created by using our system. We 
are eager to observe the progress in pursuing both the above and other biomedical applications 
as our readily adopted protease specificity engineering technology is deployed and 
implemented. 
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